{"gene":"MAFA","run_date":"2026-04-28T18:30:27","timeline":{"discoveries":[{"year":2002,"finding":"Mammalian MafA was identified as the RIPE3b1 factor that binds the insulin gene enhancer element RIPE3b and activates insulin gene expression. Biochemical purification from beta-cell nuclear extracts identified RIPE3b1 as a mammalian homologue of avian MafA/L-Maf, with selective expression in pancreatic beta but not alpha cells.","method":"Biochemical purification, DNA-binding assays (EMSA), luciferase reporter assays, RT-PCR","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1-2 — biochemical purification plus functional binding and transactivation assays; replicated in same year by independent group (PMID:12368292)","pmids":["12011435","12368292"],"is_preprint":false},{"year":2002,"finding":"MafA protein and mRNA are up-regulated by glucose in beta cells, consistent with glucose-regulated binding of MafA to the RIPE3b element in beta-cell nuclear extracts. A dominant-negative form of MafA inhibited insulin promoter activity, demonstrating direct transcriptional activation.","method":"RT-PCR, EMSA, luciferase reporter assays with dominant-negative constructs","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods (EMSA, reporter assay, dominant-negative), replicated across labs","pmids":["12368292"],"is_preprint":false},{"year":2001,"finding":"MafA (quail) is phosphorylated at serines 14 and 65 within its transactivation domain by ERK2 in vitro. Mutation of these residues to alanine severely impairs transcriptional activity and abolishes MafA's ability to induce QR1 expression and neuroretina-to-lens transdifferentiation, establishing phosphorylation as essential for MafA biological activity.","method":"In vitro kinase assays with ERK2/p38/JNK/ERK5, site-directed mutagenesis (S14A, S65A), luciferase reporter assays, in ovo electroporation","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1 — in vitro kinase reconstitution plus mutagenesis plus functional readouts","pmids":["11416124"],"is_preprint":false},{"year":2005,"finding":"MafA interacts directly with endogenous PDX-1 and BETA2 (NeuroD) in beta cells, forming a complex that synergistically activates the insulin gene promoter. Synergistic activation required intact MafA transactivation and DNA-binding domains. Dominant-negative and siRNA-mediated knockdown of MafA profoundly reduced insulin promoter activity in beta-cell lines.","method":"Co-immunoprecipitation (endogenous proteins), GST pull-down, luciferase reporter assays, dominant-negative constructs, siRNA knockdown, adenoviral overexpression in rat islets","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 — reciprocal Co-IP and GST pulldown plus functional epistasis via mutagenesis and siRNA, replicated across multiple assay systems","pmids":["15665000"],"is_preprint":false},{"year":2004,"finding":"MafA is the only beta-cell-specific insulin gene activator and selectively induces endogenous insulin transcription in non-beta cells. MafA expression is first detected in insulin-producing cells during the second principal phase of beta-cell differentiation and is absent in Nkx6.1-null pancreata that lack second-phase beta cells, placing MafA downstream of Nkx6.1.","method":"Ectopic expression in non-beta cell lines, immunohistochemistry in Nkx6.1-/- pancreata, RT-PCR","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"Medium","confidence_rationale":"Tier 2-3 — ectopic expression and KO mouse epistasis; single lab","pmids":["14973194"],"is_preprint":false},{"year":2005,"finding":"MafA-deficient mice develop glucose intolerance and diabetes mellitus. Glucose-, arginine-, and KCl-stimulated insulin secretion are severely impaired despite normal insulin content. Transcripts for insulin 1, insulin 2, Pdx1, Beta2, and Glut-2 are diminished in MafA-deficient islets, establishing MafA as a key in vivo regulator of glucose-stimulated insulin secretion.","method":"Targeted gene knockout in mice, glucose/arginine/KCl tolerance tests, RT-PCR, islet isolation and secretion assays","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 — in vivo knockout with multiple physiological phenotypic readouts and target gene analysis","pmids":["15923615"],"is_preprint":false},{"year":2005,"finding":"MafA overexpression together with PDX-1 and NeuroD markedly increases insulin gene expression and protein in liver, and dramatically ameliorates glucose tolerance in streptozotocin-induced diabetic mice, demonstrating that the combination of these three transcription factors is sufficient to reprogram non-beta cells toward insulin production.","method":"Adenoviral overexpression in vivo, glucose tolerance testing in diabetic mice, RT-PCR, Western blot","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 — in vivo functional rescue experiment; single lab","pmids":["15664997"],"is_preprint":false},{"year":2005,"finding":"FoxO1 forms a complex with PML and SIRT1 to activate MafA (and NeuroD) expression, protecting beta cells against oxidative stress. Acetylation-defective FoxO1 mutants fail to associate with PML, are subject to ubiquitin-dependent degradation, and cannot sustain MafA expression. Hyperglycemia suppresses MafA expression in vivo, and transgenic constitutively nuclear FoxO1 prevents this suppression.","method":"Co-immunoprecipitation (FoxO1-Pml-Sirt1 complex), acetylation-defective/mimicking mutants, transgenic mice with nuclear FoxO1, in vivo MafA expression analysis","journal":"Cell metabolism","confidence":"High","confidence_rationale":"Tier 2 — Co-IP of complex, mutagenesis, and transgenic mouse epistasis; multiple orthogonal approaches","pmids":["16154098"],"is_preprint":false},{"year":2005,"finding":"MafA phosphorylation by p38 MAP kinase occurs at threonine 113, threonine 57, and serine 272 (identified by mass spectrometry and Western blot). Mutation of these residues severely impairs MafA biological activity. p38 also phosphorylates MafB and c-Maf, implicating the p38 pathway as a novel regulator of large Maf transcription factors.","method":"Western blot, mass spectrometry, in vitro kinase assay with p38, site-directed mutagenesis","journal":"FEBS letters","confidence":"High","confidence_rationale":"Tier 1 — in vitro kinase assay plus mass spectrometry identification of phosphosites plus mutagenesis","pmids":["15963504"],"is_preprint":false},{"year":2006,"finding":"Beta-cell-specific MafA transcription is controlled by region 3 (bp -8118 to -7750) of the mafA promoter. FoxA2, Nkx2.2, and PDX-1 were shown to specifically bind to region 3 in vivo (by ChIP) and activate MafA transcription through this region. siRNA knockdown of PDX-1 decreased mafA mRNA; MafA was absent in Nkx2.2-null pancreata.","method":"Chromatin immunoprecipitation (ChIP), luciferase reporter assays, siRNA knockdown, Nkx2.2 knockout mouse analysis, species conservation analysis","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 — ChIP plus reporter mutagenesis plus in vivo KO epistasis; replicated across multiple approaches","pmids":["16847327"],"is_preprint":false},{"year":2006,"finding":"MafA overproduction enhances binding to the insulin promoter and increases insulin mRNA and protein, while dominant-negative MafA diminishes both. MafA regulates expression of glucokinase, Glut2, PDX1, NKX6-1, GLP1R, PCSK1, and pyruvate carboxylase in INS-1 beta cells, establishing MafA as a master regulator of genes critical for metabolism-secretion coupling.","method":"Stable INS-1 cell lines with inducible MafA overexpression or dominant-negative MafA, EMSA, RT-PCR, insulin secretion assays","journal":"Diabetologia","confidence":"High","confidence_rationale":"Tier 2 — inducible gain/loss-of-function with multiple molecular endpoints; thorough functional characterization","pmids":["17149590"],"is_preprint":false},{"year":2006,"finding":"During embryonic pancreatic development, a switch from MafB to MafA expression accompanies beta-cell differentiation. Beta-cell differentiation proceeds through a MafB+/MafA-/Ins+ intermediate cell to a MafB-/MafA+/Ins+ mature state, and MafB-to-MafA transition follows induction of high PDX-1 expression. MafA, MafB, and cMaf can each activate insulin and glucagon reporter constructs, demonstrating functional redundancy, yet display distinct cell-type-specific expression.","method":"Immunohistochemistry, co-immunofluorescence, luciferase reporter assays with ectopic Maf factor expression","journal":"Developmental biology","confidence":"Medium","confidence_rationale":"Tier 2-3 — developmental lineage mapping plus reporter assays; single lab","pmids":["16580660"],"is_preprint":false},{"year":2006,"finding":"Glucose induces MafA expression in beta-cell lines via the hexosamine biosynthetic pathway. Glucosamine stimulates MafA expression in the absence of high glucose; inhibition of hexosamine biosynthetic pathway abolishes glucose-induced MafA; and inhibition of O-GlcNAcase (which removes O-GlcNAc from proteins) stimulates MafA expression at low glucose, implicating O-linked glycosylation of an unknown protein as necessary for glucose-dependent MafA induction.","method":"Pharmacological inhibition of hexosamine pathway (azaserine), glucosamine supplementation, O-GlcNAcase inhibitors, RT-PCR, Western blot in INS-1 and MIN6 cells","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 — multiple pharmacological interventions converging on same pathway; single lab","pmids":["17142462"],"is_preprint":false},{"year":2007,"finding":"MafA protein stability is regulated by glucose through glycogen synthase kinase 3 (GSK3)-mediated phosphorylation at multiple N-terminal sites in beta cells. Mutational analysis and pharmacological GSK3 inhibition demonstrated that constitutive GSK3 phosphorylation is a prerequisite for rapid MafA degradation under low-glucose conditions, and glucose stabilizes MafA by modulating this pathway.","method":"In vitro kinase assays, site-directed mutagenesis of phosphorylation sites, pharmacological GSK3 inhibition in MIN6 cells, cycloheximide chase experiments","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1-2 — mutagenesis plus pharmacological inhibition plus kinase assay; multiple orthogonal approaches","pmids":["17682063"],"is_preprint":false},{"year":2007,"finding":"RIPE3b1/MafA binds directly to Area II of the pdx-1 gene 5'-flanking region (sequence blocks B4/5) with the same molecular mass and binding specificity as the insulin C1/RIPE3b1-binding protein. ChIP confirmed MafA binding to the Area II region of the endogenous pdx-1 gene, establishing that MafA directly regulates pdx-1 transcription.","method":"EMSA, molecular weight determination by gel fractionation, ChIP, Area II reporter assays with mutated binding sites","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 — ChIP plus binding specificity assays plus reporter mutagenesis","pmids":["12551916"],"is_preprint":false},{"year":2008,"finding":"MafA and MafB regulate Pdx1 transcription exclusively through Area II of the Pdx1 promoter in beta cells. In adult islets only MafA (not MafB) is bound to Area II by quantitative ChIP. In embryonic day 18.5 beta cells, both MafA and MafB are bound to Area II. A transgene driven by Pdx1 Areas I+II was severely compromised in MafB-/- mice, confirming MafB's requirement for Pdx1 expression during development.","method":"Quantitative ChIP, luciferase reporter assays, MafB knockout mouse analysis, transgenic reporter mice","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 — quantitative ChIP plus genetic epistasis (KO mice) plus reporter assays","pmids":["18522939"],"is_preprint":false},{"year":2008,"finding":"Phosphorylation at Ser65 of mammalian MafA governs both protein stability and transactivation potential. Ser65 phosphorylation acts as the initial degradation signal, with ubiquitinylation occurring within the C-terminus (aa 234-359). Ser65Glu (phosphomimetic) produces an unstable but transactivation-potent protein; Ser65Ala blocks degradation but reduces transactivation. Ser14 phosphorylation enhances activation without affecting turnover.","method":"Site-directed mutagenesis (S65E, S65D, S65A, S14A), cycloheximide chase, ubiquitinylation assays, luciferase reporter assays, chimeric/deletion constructs","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — multiple phosphomimetic and phosphoablative mutations plus ubiquitinylation assay plus functional readouts in same study","pmids":["19004825"],"is_preprint":false},{"year":2008,"finding":"MafA is post-translationally modified by SUMO-1 and SUMO-2 at Lys32. SUMOylation increases under low glucose or hydrogen peroxide conditions. A SUMOylation-deficient mutant (K32R) shows increased transcriptional activity toward the insulin gene promoter and increased suppression of the CHOP-10 promoter. SUMOylation does not affect nuclear localization or ubiquitin-dependent degradation of MafA.","method":"SUMO modification assays, site-directed mutagenesis (K32R), luciferase reporter assays, beta-cell treatment with low glucose and H2O2, nuclear localization assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1-2 — site-specific mutagenesis plus functional transactivation assays plus conditions-dependent SUMO modification","pmids":["19029092"],"is_preprint":false},{"year":2009,"finding":"p38 MAPK is a major regulator of MafA protein stability specifically under oxidative stress. p38 MAPK inhibition enhances MafA stability under both low and high glucose; simultaneous mutation of Thr57 and Thr134 to alanine prevents p38-mediated degradation. Under oxidative stress, reduced GSK3-pathway activity (via decreased PA28γ) makes p38 MAPK the dominant degradation pathway.","method":"Pharmacological p38 inhibition (SB203580), site-directed mutagenesis (T57A, T134A double mutant), cycloheximide chase in MIN6 and mouse islets, oxidative stress experiments","journal":"Molecular endocrinology","confidence":"High","confidence_rationale":"Tier 2 — pharmacological inhibition plus mutagenesis plus islet validation; multiple conditions tested","pmids":["19407223"],"is_preprint":false},{"year":2009,"finding":"MafA expression in Pdx1+ pancreatic progenitors is detrimental to pancreatic development. Transgenic MafA expression in Pdx1+ cells reduces pancreatic mass and progenitor proliferation, at least partially through induction of cyclin kinase inhibitors p27 and p57, and disproportionately inhibits endocrine cell formation.","method":"Transgenic mouse model (MafA in Pdx1+ cells), immunohistochemistry, BrdU proliferation assay, cyclin inhibitor analysis (p27, p57)","journal":"Developmental biology","confidence":"Medium","confidence_rationale":"Tier 2 — transgenic gain-of-function with mechanistic target identification; single lab","pmids":["19576197"],"is_preprint":false},{"year":2009,"finding":"Specific subtypes of low-threshold mechanoreceptors (LTMs) in dorsal root ganglia selectively express MafA. In Ret-deficient mice, MafA expression is reduced and central/peripheral LTM projections are compromised. In MafA mutant mice, a discrete subset of LTMs displays altered neurotrophic factor receptor expression, establishing a genetic interaction between Ret signaling and MafA in LTM specification.","method":"Immunohistochemistry, in situ hybridization, Ret knockout mouse analysis, MafA mutant mouse analysis, axon projection tracing","journal":"Neuron","confidence":"High","confidence_rationale":"Tier 2 — two independent knockout models with distinct phenotypic readouts establishing genetic epistasis","pmids":["20064392"],"is_preprint":false},{"year":2010,"finding":"Phosphorylation within the MafA N-terminal transactivation domain (aa 1-72) is required for C-terminal dimerization and DNA binding. Dephosphorylation abolishes detection of MafA dimers and dramatically reduces DNA-binding ability. Analysis of MafA/MafB chimeras showed that the C-terminal dimerization region of MafA (aa 279-359) confers phosphorylation-sensitive DNA binding, whereas the homologous MafB region conveys phosphorylation-independent binding.","method":"Mass spectrometry (phosphosite identification), dephosphorylation assays, MafA/MafB chimeric protein analysis, EMSA, mutagenesis","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1-2 — mass spectrometry plus biochemical dephosphorylation plus chimeric protein domain mapping","pmids":["20208071"],"is_preprint":false},{"year":2010,"finding":"MafA regulates postnatal beta-cell function by controlling expression of genes for glucose sensing, hormone processing, vesicle formation, and insulin secretion. Microarray profiling of MafB-/- embryonic pancreata and adult MafA-null islets showed overlapping target genes, demonstrating sequential regulation: MafB controls these genes developmentally and MafA sustains their expression in adults.","method":"Microarray profiling of MafB-/- (E18.5) and pancreas-specific MafA-null adult islets, quantitative RT-PCR, in situ hybridization, immunohistochemistry","journal":"Diabetes","confidence":"High","confidence_rationale":"Tier 2 — genome-wide transcriptomic analysis in two distinct KO models with validation","pmids":["20627934"],"is_preprint":false},{"year":2010,"finding":"Mafa overexpression in neonatal rat islets (via adenovirus) induces acquisition of glucose-responsive insulin secretion, increasing both the percentage of secreting beta cells and insulin secreted per cell, approaching adult levels. Mafa specifically upregulates Neurod1, Nkx6-1, glucokinase, and Glp1r mRNAs, identifying a gene expression program downstream of Mafa that drives functional maturation.","method":"Adenoviral Mafa overexpression in P2 rat islets, static insulin secretion assays, reverse haemolytic plaque assay (RHPA), quantitative RT-PCR","journal":"Diabetologia","confidence":"High","confidence_rationale":"Tier 2 — adenoviral gain-of-function with functional secretion readout and target gene identification; replicated across assay systems","pmids":["21190012"],"is_preprint":false},{"year":2010,"finding":"c-Jun, upregulated by reactive oxygen species under diabetic conditions, suppresses MafA expression. Adenoviral overexpression of c-Jun in MIN6 cells and isolated islets significantly decreased MafA protein and mRNA, with concomitant suppression of insulin expression. MafA overexpression restored insulin promoter activity suppressed by c-Jun, placing c-Jun upstream of MafA in a ROS-mediated pathway.","method":"Adenoviral c-Jun overexpression in MIN6 and primary islets, Western blot, immunohistochemistry in db/db mice, insulin promoter luciferase reporter","journal":"Diabetes","confidence":"Medium","confidence_rationale":"Tier 2 — gain-of-function plus epistasis rescue experiment; single lab","pmids":["20424231"],"is_preprint":false},{"year":2011,"finding":"ATF2 is a component of the RIPE3b1 activator complex. ATF2 alone cannot bind the C1/RIPE3b element but acquires binding capacity through complex formation with MafA. ATF2 also interacts with PDX-1 and BETA2. Co-expression of ATF2 with MafA, PDX-1, and BETA2 results in synergistic insulin promoter activation. RNAi knockdown of ATF2 in MIN6 cells reduces endogenous insulin mRNA.","method":"Co-immunoprecipitation (ATF2-MafA interaction), EMSA with ATF2/MafA complex, luciferase reporter assays, RNAi knockdown, immunohistochemistry of mouse pancreas","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 — Co-IP plus EMSA plus RNAi knockdown with functional readout","pmids":["21278380"],"is_preprint":false},{"year":2011,"finding":"Proteasome activator PA28γ (REGγ/PSME3) stimulates GSK3-phosphorylated MafA degradation via the 20S proteasome. PA28γ binds to phosphorylated MafA; alanine substitutions at GSK3 phosphorylation sites (Ser49, Thr53, Thr57, Ser61, Ser65) prevent PA28γ binding and confer resistance to degradation. PA28γ-mediated MafA degradation occurs through a distinct mechanism from its degradation of p21.","method":"Co-immunoprecipitation (PA28γ-MafA), site-directed mutagenesis (phosphorylation site alanine substitutions), proteasome activity assays, luciferase reporter assays, PA28γ mutant analysis (N151Y, K188D)","journal":"Journal of molecular endocrinology","confidence":"High","confidence_rationale":"Tier 1-2 — Co-IP plus mutagenesis plus mechanistic differentiation from known PA28γ substrate; multiple orthogonal approaches","pmids":["21646385"],"is_preprint":false},{"year":2010,"finding":"SUMOylation of MafA at Lys32 negatively regulates its transcriptional and oncogenic activities. A K32R SUMOylation-deficient mutant more potently transactivates crystallin and insulin gene promoters, more efficiently induces ectopic crystallin expression in developing chick embryo, and has enhanced ability to induce colony formation in DF-1 fibroblasts, demonstrating that SUMO modification restrains both transcriptional and transforming activities.","method":"Site-directed mutagenesis (K32R), luciferase reporter assays, in ovo electroporation, colony formation assay in DF-1 cells","journal":"Genes to cells","confidence":"High","confidence_rationale":"Tier 1-2 — site-specific mutation with multiple functional readouts across cell types","pmids":["20718938"],"is_preprint":false},{"year":2012,"finding":"miR-30d induces MafA expression by directly targeting MAP4K4 (a TNF-α-activated kinase), thereby de-repressing MafA. Overexpression of miR-30d prevents TNF-α-induced reduction in both MafA and IRS2. Overexpression of MAP4K4 suppresses MafA, and miR-30d overexpression protects against MAP4K4-mediated suppression of insulin transcription and secretion.","method":"miR-30d overexpression in beta cells, luciferase 3'UTR reporter assay (MAP4K4 as direct target), Western blot, RT-PCR, insulin secretion assays, db/db mouse islet analysis","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2-3 — 3'UTR reporter validation plus gain-of-function experiments; single lab","pmids":["22733810"],"is_preprint":false},{"year":2013,"finding":"Thyroid hormone (triiodothyronine/T3) directly binds to the Mafa promoter region via thyroid hormone receptor, activating Mafa transcription. In vitro exposure of immature rat islets to T3 enhanced Mafa expression and glucose-responsive insulin secretion, effects abolished by dominant-negative Mafa. In vivo, neonatal T3 supplementation accelerated metabolic development; T3 inhibition delayed it.","method":"ChIP (thyroid hormone receptor binding to Mafa promoter), EMSA, luciferase reporter assay, dominant-negative Mafa in vitro, neonatal rat T3 manipulation in vivo","journal":"Diabetes","confidence":"High","confidence_rationale":"Tier 1-2 — direct receptor-ligand ChIP plus EMSA plus functional reporter plus dominant-negative epistasis plus in vivo intervention","pmids":["23305647"],"is_preprint":false},{"year":2013,"finding":"p38 MAPK directly binds MafA and triggers its degradation via the ubiquitin-proteasomal pathway. Under oxidative stress (but not non-oxidative conditions), MafA degradation depends on p38-mediated phosphorylation at Thr134 (not Thr57). Expression of T134A-MafA (but not T57A-MafA) reduced oxidative stress-mediated loss of glucose-stimulated insulin secretion, independent of p38 action on protein kinase D.","method":"Co-immunoprecipitation (p38-MafA direct binding), site-directed mutagenesis (T134A, T57A), proteasome inhibitor experiments, insulin secretion assays under oxidative stress","journal":"Molecular endocrinology","confidence":"High","confidence_rationale":"Tier 2 — direct binding by Co-IP plus site-specific mutagenesis plus functional insulin secretion readout","pmids":["23660596"],"is_preprint":false},{"year":2014,"finding":"MafA is required for postnatal beta-cell proliferation via the prolactin signaling pathway. MafA directly transactivates the prolactin receptor (Prlr) promoter, and loss of MafA reduces Prlr and Cyclin D2 (Ccnd2) expression. Prolactin stimulation of beta cells triggers phosphorylation and translocation of Stat5B and increases nuclear Cyclin D2 pool via Prlr/Jak2 signaling, resulting in proliferation. MafA-null mice show impaired beta-cell proliferation at 4 weeks.","method":"Transcriptome analysis (MafA KO islets), Prlr promoter luciferase reporter and ChIP, prolactin stimulation of beta cells, Stat5B phosphorylation assays, BrdU proliferation in MafA-null mice","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 2 — ChIP plus promoter reporter plus pathway stimulation plus in vivo KO phenotype","pmids":["25126749"],"is_preprint":false},{"year":2014,"finding":"Loss of MafA reduces the beta-to-alpha cell ratio without hyperglycemia, and lineage tracing shows that most MafA-null former beta cells lose insulin expression while a minority convert to glucagon-expressing cells. MafA-null islets upregulate genes normally repressed in mature beta cells and transiently express endocrine progenitor transcription factors, hallmarks of dedifferentiation. This dedifferentiation also occurs in db/db and STZ diabetic models alongside MafB re-expression.","method":"MafA knockout mice, lineage tracing (Cre-lox), immunohistochemistry, gene expression analysis of dedifferentiation markers","journal":"Diabetologia","confidence":"High","confidence_rationale":"Tier 2 — genetic lineage tracing plus KO phenotyping with molecular characterization of cell fate","pmids":["25500951"],"is_preprint":false},{"year":2014,"finding":"MafA becomes functionally essential to beta cells soon after birth. Islet organization, beta-cell mass, and function are compromised by 3 weeks in Mafa-null mice and earlier in Mafa/Mafb compound mutants. Genome-wide microarray identified MafA targets including cyclin D2 (controlling beta-cell replication) and genes affecting granule docking (affecting first-phase insulin secretion), substantiated by electron microscopy.","method":"Conditional Mafa knockout mice (MafaΔpanc), compound Mafa/Mafb mutants, genome-wide microarray, electron microscopy of granule docking, metabolic assays","journal":"Diabetes","confidence":"High","confidence_rationale":"Tier 2 — multiple KO models + genome-wide profiling + ultrastructural EM + metabolic functional assays","pmids":["24520122"],"is_preprint":false},{"year":2015,"finding":"MLL3 and MLL4 histone H3K4 methyltransferase complexes bind to both MafA and MAFB transcription factors in beta cells. Unbiased in-cell biochemical and mass spectrometry identified all subunits of MLL3/4 complexes as MafA-interacting proteins. MafA is associated with the ~1.5 MDa MLL3/4 complexes in size-fractionated beta-cell extracts. Knockdown of NCOA6 (core MLL3/4 subunit) reduces expression of MafA/MafB target genes.","method":"In-cell biochemistry plus mass spectrometry (unbiased pulldown), size-fractionation/Co-IP, NCOA6 siRNA knockdown, NCoA6 conditional knockout in beta cells","journal":"Diabetes","confidence":"High","confidence_rationale":"Tier 2 — unbiased mass spectrometry identification plus Co-IP in native complex plus genetic validation (KO mice)","pmids":["26180087"],"is_preprint":false},{"year":2015,"finding":"HMGA1 physically interacts with PDX-1 and MafA (both in vitro by GST pulldown and in vivo by Co-IP). HMGA1 overexpression enhances the transactivating activity of PDX-1 and MafA on human and mouse insulin promoters; HMGA1 knockdown reduces this activity. High glucose stimulus increases HMGA1 binding to the insulin gene promoter (ChIP), indicating HMGA1 acts as a glucose-sensitive co-activator.","method":"GST pull-down, Co-immunoprecipitation, ChIP, luciferase reporter assays, siRNA knockdown, glucose stimulation","journal":"Frontiers in endocrinology","confidence":"Medium","confidence_rationale":"Tier 2-3 — Co-IP plus GST pulldown plus ChIP plus functional reporter; single lab","pmids":["25628604"],"is_preprint":false},{"year":2016,"finding":"MAFA directly controls ANS-mediated insulin secretion by activating transcription of nicotinic receptor genes ChrnB2 and ChrnB4, and adrenergic receptor gene Adra2A. Acetylcholine-mediated insulin secretion requires nicotinic signaling, and nicotinic receptor expression is positively correlated with insulin secretion. MAFA binding to the ChrnB4 regulatory region was demonstrated by ChIP.","method":"MafA-deficient mouse model, ChIP (MafA binding to nicotinic receptor gene loci), pharmacological nicotinic receptor blockade, insulin secretion assays, correlation with human islet data","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 2 — ChIP plus KO mouse plus pharmacological epistasis plus functional secretion assays","pmids":["26904947"],"is_preprint":false},{"year":2017,"finding":"Mafa potentiates PDX-1's ability to induce beta-cell formation from Ngn3-positive endocrine precursors and enables PDX-1 to produce beta cells from glucagon-positive alpha cells in vivo. Transgenic conditional expression of Mafa and/or Pdx1 in Ngn3+ progenitors and glucagon+ alpha cells demonstrated that Mafa is required to permit Pdx1-driven alpha-to-beta transdifferentiation.","method":"Conditional transgenic mouse models (Mafa and/or Pdx1 in Ngn3-Cre or glucagon-Cre lineages), lineage tracing, immunohistochemistry, hormone expression analysis","journal":"Diabetes","confidence":"High","confidence_rationale":"Tier 2 — in vivo genetic epistasis using multiple conditional transgenic models","pmids":["28223284"],"is_preprint":false},{"year":2018,"finding":"A missense MAFA mutation (p.Ser64Phe) causes familial insulinomatosis and diabetes by impairing phosphorylation within the transactivation domain, profoundly increasing MAFA protein stability under both high and low glucose conditions. The p.Ser64Phe mutation also enhances the transactivation potential of MAFA in beta-cell lines.","method":"Exome sequencing, functional studies of p.Ser64Phe in beta-cell lines (protein stability assays with cycloheximide chase, luciferase reporter for transactivation), phosphorylation analysis","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 — disease-associated variant with mechanistic characterization (stability + transactivation assays) replicated in two independent families","pmids":["29339498"],"is_preprint":false},{"year":2018,"finding":"Long noncoding RNA Meg3 epigenetically regulates MafA expression in beta cells via EZH2-mediated H3K27 trimethylation of Rad21, Smc3, and Sin3α promoters. Knockdown of Meg3 or Ezh2 upregulates Rad21, Smc3, and Sin3α, which directly repress the MafA promoter. Inhibition of Rad21, Smc3, or Sin3α individually leads to upregulated MafA expression and increased insulin production.","method":"ChIP-qPCR (EZH2/H3K27me3 at Rad21/Smc3/Sin3α promoters), RNA immunoprecipitation-qPCR (Meg3-EZH2 binding), RNAi knockdown of Meg3/Ezh2/Rad21/Smc3/Sin3α, Western blot, RT-PCR in MIN6 and mouse islets","journal":"Cellular physiology and biochemistry","confidence":"Medium","confidence_rationale":"Tier 2 — ChIP plus RIP plus multiple RNAi validations; single lab","pmids":["29529600"],"is_preprint":false},{"year":2019,"finding":"MafA directly regulates the voltage-gated Ca2+ channel subunit CaVγ4 (Cacng4) in beta cells. ChIP confirmed MafA binding to the CaVγ4 gene. CaVγ4 reduction in MafA-knockout mice suppresses L-type CaV1.2 and CaV1.3 expression, thereby suppressing voltage-gated Ca2+ entry and glucose-stimulated insulin exocytosis.","method":"ChIP (MafA binding to CaVγ4 gene), beta-cell-specific MafA knockout mice, patch-clamp electrophysiology (Ca2+ channel recordings), insulin exocytosis assays","journal":"Communications biology","confidence":"High","confidence_rationale":"Tier 2 — ChIP plus genetic KO plus electrophysiology plus functional exocytosis assay","pmids":["30911681"],"is_preprint":false},{"year":2020,"finding":"Kindlin-2, through its C-terminal region, directly binds to and stabilizes MafA protein in beta cells. Kindlin-2 deletion causes severe diabetes-like phenotypes; reduced MafA activity impairs insulin expression. Kindlin-2 loss also activates GSK-3β and downregulates β-catenin, reducing beta-cell proliferation and mass.","method":"Co-immunoprecipitation (Kindlin-2–MafA interaction, C-terminal domain mapping), Kindlin-2 conditional knockout mice, insulin secretion from primary human and mouse islets, Ca2+ release assays, GSK-3β/β-catenin pathway analysis","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 — Co-IP with domain mapping plus conditional KO with mechanistic pathway analysis","pmids":["31980627"],"is_preprint":false},{"year":2021,"finding":"The MAFA S64F mutation causes sex-biased beta-cell dysfunction by inducing premature aging and cellular senescence selectively in males. Male MafaS64F/+ mice display transiently higher MafA protein levels preceding glucose intolerance. MAFAS64F production in male human beta cells accelerates cellular senescence and increases senescence-associated secretory proteins compared to cells expressing MAFAWT.","method":"S64F knock-in mouse model, glucose tolerance testing, sex-stratified analysis, gene expression profiling (Ca2+ signaling, DNA damage, aging/senescence pathways), cellular senescence assays in human beta cells","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 2 — knock-in mouse model plus human cell validation with multiple molecular senescence readouts","pmids":["34644565"],"is_preprint":false},{"year":2022,"finding":"METTL3-mediated m6A methylation regulates MafA mRNA stability in beta cells. Silencing METTL3 reduces m6A levels, MafA mRNA stability, and MafA protein expression, impairing glucose-stimulated insulin secretion. Overexpression of MafA rescues the decrease in GSIS caused by METTL3 silencing, while MafA silencing blocks METTL3 overexpression-mediated rescue, placing MafA downstream of METTL3/m6A modification.","method":"m6A-seq/quantification, METTL3 siRNA knockdown and overexpression, mRNA stability assays, luciferase reporter (MafA mRNA), MafA overexpression rescue, insulin secretion assays","journal":"Frontiers in endocrinology","confidence":"Medium","confidence_rationale":"Tier 2 — m6A quantification plus stability assay plus bidirectional epistasis rescue experiment; single lab","pmids":["35872977"],"is_preprint":false},{"year":1998,"finding":"Avian mafA encodes a novel large Maf protein expressed in the differentiating neuroretina. MafA binds to MARE sequences and heterodimerizes with v-Maf, MafB, Jun, and Fos (but not small Maf proteins MafF/MafK). Increased MafA expression induces sustained proliferation of postmitotic quail neuroretinal cells.","method":"cDNA cloning, EMSA (MARE binding), co-immunoprecipitation/heterodimerization assays, ectopic expression in quail neuroretinal cells","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2-3 — initial characterization of dimerization partners plus functional proliferation assay; foundational paper","pmids":["9674710"],"is_preprint":false},{"year":2003,"finding":"MafA's strong cell-transforming ability maps to its DNA-binding domain. Chimeras of MafA and MafB correlate the strong transformation capacity of MafA with its DNA-binding domain, while weak transactivation also maps to this domain. Cell transformation and transactivation by MafA are controlled by phosphorylation of two conserved serine residues in the transactivation domain.","method":"MafA/MafB chimeric protein analysis, chicken embryo fibroblast transformation assay, luciferase reporter assays, site-directed mutagenesis of serine residues","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 — chimeric domain mapping plus functional transformation assay plus mutagenesis; single lab","pmids":["12970735"],"is_preprint":false},{"year":2015,"finding":"MafA directly binds to and activates MaoA and MaoB (monoamine oxidase) transcriptional control sequences in pancreatic beta cells (demonstrated by ChIP). MaoA and MaoB are expressed in mouse islet beta cells; inhibition of Mao activity reduces insulin secretion. MaoB expression is reduced in MafA-deficient mice and in type 2 diabetic mouse and human islets.","method":"ChIP (MafA binding to MaoA/MaoB gene regulatory regions), MafA-deficient mouse analysis, pharmacological Mao inhibition, insulin secretion assays","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2-3 — ChIP plus KO mouse plus pharmacological inhibition; single lab","pmids":["26546820"],"is_preprint":false},{"year":2021,"finding":"PPP1R1A (protein phosphatase 1 inhibitor protein 1A) is a MafA target gene required for GLP1R-mediated amplification of glucose-stimulated insulin secretion. MafA loss or acute knockdown reduces PPP1R1A expression. PPP1R1A silencing impairs GSIS amplification, PKA-target phosphorylation, mitochondrial coupling efficiency, and expression of critical beta-cell genes including MafA, Pdx1, NeuroD1, and Pax6.","method":"MafA-deficient mouse islet transcriptomics, siRNA knockdown of PPP1R1A in INS1 cells, insulin secretion assays (GLP1-amplified GSIS), PKA substrate phosphorylation assays, mitochondrial coupling efficiency measurements","journal":"Metabolism: clinical and experimental","confidence":"Medium","confidence_rationale":"Tier 2 — KO transcriptomics plus RNAi with functional secretion and pathway assays; single lab","pmids":["33631146"],"is_preprint":false}],"current_model":"MAFA is a beta-cell-enriched basic leucine zipper (bZIP) transcription factor that binds the insulin gene C1/RIPE3b element and synergistically activates insulin transcription with PDX-1 and BETA2/NeuroD via a direct physical complex; its activity, stability, and DNA-binding capacity are tightly regulated by phosphorylation (by GSK3, ERK2, p38 MAPK) at multiple N-terminal serines/threonines—which govern ubiquitin-proteasome-mediated degradation facilitated by PA28γ—as well as by SUMOylation at Lys32 (which represses transactivation) and glucose-driven stabilization via the hexosamine/O-GlcNAc pathway; upstream, FoxO1/PML/SIRT1, thyroid hormone receptor, and FoxA2/Nkx2.2/PDX-1 control MAFA transcription through the conserved region 3 of its promoter, while c-Jun and p38 MAPK suppress it under diabetic/oxidative-stress conditions; MafA directly regulates a broad beta-cell gene program including Pdx1, Glut2, glucokinase, GLP1R, nicotinic receptors (ChrnB2/B4), Ca2+ channel subunit CaVγ4, monoamine oxidases, PPP1R1A, and prolactin receptor (driving postnatal beta-cell proliferation via Jak2/Stat5B/Cyclin D2); in vivo, MafA is dispensable for initial beta-cell specification but essential for postnatal functional maturation, maintenance of beta-cell identity (loss causes dedifferentiation and alpha-cell conversion), and neurosensory low-threshold mechanoreceptor specification via a Ret-MafA genetic interaction; disease-associated gain-of-stability mutations (S64F) increase protein levels and enhance transactivation, causing insulinomatosis or diabetes through premature senescence in a sex-biased manner."},"narrative":{"teleology":[],"mechanism_profile":{"molecular_activity":[],"localization":[],"pathway":[],"complexes":[],"partners":[],"other_free_text":[]},"mechanistic_narrative":"Insufficient on-target evidence to synthesize a narrative — discovery timeline does not match the canonical MAFA protein."},"prefetch_data":{"uniprot":{"accession":"Q8NHW3","full_name":"Transcription factor MafA","aliases":["Pancreatic beta-cell-specific transcriptional activator","RIPE3b1 factor","V-maf musculoaponeurotic fibrosarcoma oncogene homolog A"],"length_aa":353,"mass_kda":37.0,"function":"Transcription factor that activates insulin gene expression (PubMed:12011435, PubMed:15993959). Acts synergistically with NEUROD1/BETA2 and PDX1 (PubMed:15993959). Binds the insulin enhancer C1/RIPE3b element (PubMed:12011435). Binds to consensus TRE-type MARE 5'-TGCTGACTCAGCA-3' DNA sequence (PubMed:23148532, PubMed:29339498)","subcellular_location":"Nucleus","url":"https://www.uniprot.org/uniprotkb/Q8NHW3/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/MAFA","classification":"Not Classified","n_dependent_lines":3,"n_total_lines":1208,"dependency_fraction":0.0024834437086092716},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/MAFA","total_profiled":1310},"omim":[{"mim_id":"610303","title":"MAF bZIP TRANSCRIPTION FACTOR A; MAFA","url":"https://www.omim.org/entry/610303"},{"mim_id":"608968","title":"MAF bZIP TRANSCRIPTION FACTOR B; MAFB","url":"https://www.omim.org/entry/608968"},{"mim_id":"607141","title":"GLIOMA PATHOGENESIS-RELATED PROTEIN 2; GLIPR2","url":"https://www.omim.org/entry/607141"},{"mim_id":"604882","title":"NEUROGENIN 3; NEUROG3","url":"https://www.omim.org/entry/604882"},{"mim_id":"604874","title":"KILLER CELL LECTIN-LIKE RECEPTOR, SUBFAMILY G, MEMBER 1; KLRG1","url":"https://www.omim.org/entry/604874"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enriched","tissue_distribution":"Detected in some","driving_tissues":[{"tissue":"skeletal muscle","ntpm":21.9}],"url":"https://www.proteinatlas.org/search/MAFA"},"hgnc":{"alias_symbol":["RIPE3b1","hMafA"],"prev_symbol":[]},"alphafold":{"accession":"Q96E93","domains":[{"cath_id":"3.10.100.10","chopping":"83-187","consensus_level":"high","plddt":96.2488,"start":83,"end":187}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q96E93","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q96E93-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q96E93-F1-predicted_aligned_error_v6.png","plddt_mean":81.38},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=MAFA","jax_strain_url":"https://www.jax.org/strain/search?query=MAFA"},"sequence":{"accession":"Q96E93","fasta_url":"https://rest.uniprot.org/uniprotkb/Q96E93.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q96E93/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q96E93"}},"corpus_meta":[{"pmid":"16154098","id":"PMC_16154098","title":"FoxO1 protects against pancreatic beta cell failure through NeuroD and MafA induction.","date":"2005","source":"Cell metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/16154098","citation_count":492,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15923615","id":"PMC_15923615","title":"MafA is a key regulator of glucose-stimulated insulin secretion.","date":"2005","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/15923615","citation_count":396,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12011435","id":"PMC_12011435","title":"Identification of beta-cell-specific insulin gene transcription factor RIPE3b1 as mammalian MafA.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12011435","citation_count":268,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12368292","id":"PMC_12368292","title":"MafA is a glucose-regulated and pancreatic beta-cell-specific transcriptional activator for the insulin gene.","date":"2002","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12368292","citation_count":250,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16580660","id":"PMC_16580660","title":"A switch from MafB to MafA expression accompanies differentiation to pancreatic beta-cells.","date":"2006","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/16580660","citation_count":240,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29096722","id":"PMC_29096722","title":"PDX1, Neurogenin-3, and MAFA: critical transcription regulators for beta cell development and regeneration.","date":"2017","source":"Stem cell research & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/29096722","citation_count":230,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"14973194","id":"PMC_14973194","title":"The MafA transcription factor appears to be responsible for tissue-specific expression of insulin.","date":"2004","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/14973194","citation_count":225,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20627934","id":"PMC_20627934","title":"MafA and MafB regulate genes critical to beta-cells in a unique temporal manner.","date":"2010","source":"Diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/20627934","citation_count":197,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21719305","id":"PMC_21719305","title":"MafA and MafB activity in pancreatic β cells.","date":"2011","source":"Trends in endocrinology and metabolism: TEM","url":"https://pubmed.ncbi.nlm.nih.gov/21719305","citation_count":172,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17149590","id":"PMC_17149590","title":"MAFA controls genes implicated in insulin biosynthesis and secretion.","date":"2006","source":"Diabetologia","url":"https://pubmed.ncbi.nlm.nih.gov/17149590","citation_count":167,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15665000","id":"PMC_15665000","title":"The islet beta cell-enriched MafA activator is a key regulator of insulin gene transcription.","date":"2005","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15665000","citation_count":155,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19819955","id":"PMC_19819955","title":"beta-Cell-specific overexpression of glutathione peroxidase preserves intranuclear MafA and reverses diabetes in db/db mice.","date":"2009","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/19819955","citation_count":152,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7491105","id":"PMC_7491105","title":"The reduction of insulin gene transcription in HIT-T15 beta cells chronically exposed to high glucose concentration is associated with the loss of RIPE3b1 and STF-1 transcription factor expression.","date":"1995","source":"Molecular endocrinology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/7491105","citation_count":142,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21190012","id":"PMC_21190012","title":"Mafa expression enhances glucose-responsive insulin secretion in neonatal rat beta cells.","date":"2010","source":"Diabetologia","url":"https://pubmed.ncbi.nlm.nih.gov/21190012","citation_count":132,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8613527","id":"PMC_8613527","title":"Chronic exposure of betaTC-6 cells to supraphysiologic concentrations of glucose decreases binding of the RIPE3b1 insulin gene transcription activator.","date":"1996","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/8613527","citation_count":127,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17938503","id":"PMC_17938503","title":"PDX-1 and MafA play a crucial role in pancreatic beta-cell differentiation and maintenance of mature beta-cell function.","date":"2007","source":"Endocrine journal","url":"https://pubmed.ncbi.nlm.nih.gov/17938503","citation_count":126,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23305647","id":"PMC_23305647","title":"Thyroid hormone promotes postnatal rat pancreatic β-cell development and glucose-responsive insulin secretion through MAFA.","date":"2013","source":"Diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/23305647","citation_count":119,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22733810","id":"PMC_22733810","title":"MicroRNA-30d induces insulin transcription factor MafA and insulin production by targeting mitogen-activated protein 4 kinase 4 (MAP4K4) in pancreatic β-cells.","date":"2012","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/22733810","citation_count":113,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25500951","id":"PMC_25500951","title":"MafA is critical for maintenance of the mature beta cell phenotype in mice.","date":"2014","source":"Diabetologia","url":"https://pubmed.ncbi.nlm.nih.gov/25500951","citation_count":110,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15664997","id":"PMC_15664997","title":"A crucial role of MafA as a novel therapeutic target for diabetes.","date":"2005","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15664997","citation_count":107,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24520122","id":"PMC_24520122","title":"The MafA transcription factor becomes essential to islet β-cells soon after birth.","date":"2014","source":"Diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/24520122","citation_count":106,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16847327","id":"PMC_16847327","title":"FoxA2, Nkx2.2, and PDX-1 regulate islet beta-cell-specific mafA expression through conserved sequences located between base pairs -8118 and -7750 upstream from the transcription start site.","date":"2006","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/16847327","citation_count":102,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33067121","id":"PMC_33067121","title":"Mobile health technology-supported atrial fibrillation screening and integrated care: A report from the mAFA-II trial Long-term Extension Cohort.","date":"2020","source":"European journal of internal medicine","url":"https://pubmed.ncbi.nlm.nih.gov/33067121","citation_count":98,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20064392","id":"PMC_20064392","title":"Low-threshold mechanoreceptor subtypes selectively express MafA and are specified by Ret signaling.","date":"2009","source":"Neuron","url":"https://pubmed.ncbi.nlm.nih.gov/20064392","citation_count":91,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22150363","id":"PMC_22150363","title":"Reprogramming of pancreatic exocrine cells towards a beta (β) cell character using Pdx1, Ngn3 and MafA.","date":"2012","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/22150363","citation_count":88,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20424231","id":"PMC_20424231","title":"Regulation of MafA expression in pancreatic beta-cells in db/db mice with diabetes.","date":"2010","source":"Diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/20424231","citation_count":85,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11416124","id":"PMC_11416124","title":"Phosphorylation of MafA is essential for its transcriptional and biological properties.","date":"2001","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/11416124","citation_count":84,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17636040","id":"PMC_17636040","title":"MafA regulates expression of genes important to islet beta-cell function.","date":"2007","source":"Molecular endocrinology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/17636040","citation_count":83,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29339498","id":"PMC_29339498","title":"MAFA missense mutation causes familial insulinomatosis and diabetes mellitus.","date":"2018","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/29339498","citation_count":81,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15862113","id":"PMC_15862113","title":"Relative contribution of PDX-1, MafA and E47/beta2 to the regulation of the human insulin promoter.","date":"2005","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/15862113","citation_count":81,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15993959","id":"PMC_15993959","title":"Synergistic activation of the insulin gene promoter by the beta-cell enriched transcription factors MafA, Beta2, and Pdx1.","date":"2005","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/15993959","citation_count":79,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37247623","id":"PMC_37247623","title":"Mobile Health-Technology-Integrated Care for Atrial Fibrillation: A Win Ratio Analysis from the mAFA-II Randomized Clinical Trial.","date":"2023","source":"Thrombosis and haemostasis","url":"https://pubmed.ncbi.nlm.nih.gov/37247623","citation_count":77,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10741410","id":"PMC_10741410","title":"NK cell expression of the killer cell lectin-like receptor G1 (KLRG1), the mouse homolog of MAFA, is modulated by MHC class I molecules.","date":"2000","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/10741410","citation_count":77,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17682063","id":"PMC_17682063","title":"MafA stability in pancreatic beta cells is regulated by glucose and is dependent on its constitutive phosphorylation at multiple sites by glycogen synthase kinase 3.","date":"2007","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/17682063","citation_count":69,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17785922","id":"PMC_17785922","title":"Roles and regulation of transcription factor MafA in islet beta-cells.","date":"2007","source":"Endocrine journal","url":"https://pubmed.ncbi.nlm.nih.gov/17785922","citation_count":66,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23801580","id":"PMC_23801580","title":"Ebselen treatment prevents islet apoptosis, maintains intranuclear Pdx-1 and MafA levels, and preserves β-cell mass and function in ZDF rats.","date":"2013","source":"Diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/23801580","citation_count":63,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8584024","id":"PMC_8584024","title":"The role of the insulin control element and RIPE3b1 activators in glucose-stimulated transcription of the insulin gene.","date":"1995","source":"Molecular endocrinology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/8584024","citation_count":62,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25645923","id":"PMC_25645923","title":"Preserving Mafa expression in diabetic islet β-cells improves glycemic control in vivo.","date":"2015","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/25645923","citation_count":62,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33514698","id":"PMC_33514698","title":"PDX1LOW MAFALOW β-cells contribute to islet function and insulin release.","date":"2021","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/33514698","citation_count":59,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28223284","id":"PMC_28223284","title":"Mafa Enables Pdx1 to Effectively Convert Pancreatic Islet Progenitors and Committed Islet α-Cells Into β-Cells In Vivo.","date":"2017","source":"Diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/28223284","citation_count":55,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12551916","id":"PMC_12551916","title":"The islet beta cell-enriched RIPE3b1/Maf transcription factor regulates pdx-1 expression.","date":"2003","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12551916","citation_count":54,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9674710","id":"PMC_9674710","title":"mafA, a novel member of the maf proto-oncogene family, displays developmental regulation and mitogenic capacity in avian neuroretina cells.","date":"1998","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/9674710","citation_count":54,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26180087","id":"PMC_26180087","title":"MLL3 and MLL4 Methyltransferases Bind to the MAFA and MAFB Transcription Factors to Regulate Islet β-Cell Function.","date":"2015","source":"Diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/26180087","citation_count":53,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29529600","id":"PMC_29529600","title":"Long Noncoding RNA Meg3 Regulates Mafa Expression in Mouse Beta Cells by Inactivating Rad21, Smc3 or Sin3α.","date":"2018","source":"Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/29529600","citation_count":52,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34932104","id":"PMC_34932104","title":"The Effects of Implementing a Mobile Health-Technology Supported Pathway on Atrial Fibrillation-Related Adverse Events Among Patients With Multimorbidity: The mAFA-II Randomized Clinical Trial.","date":"2021","source":"JAMA network open","url":"https://pubmed.ncbi.nlm.nih.gov/34932104","citation_count":51,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9842918","id":"PMC_9842918","title":"MAFA-L, an ITIM-containing receptor encoded by the human NK cell gene complex and expressed by basophils and NK cells.","date":"1998","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/9842918","citation_count":51,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17142462","id":"PMC_17142462","title":"Glucose induces MafA expression in pancreatic beta cell lines via the hexosamine biosynthetic pathway.","date":"2006","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17142462","citation_count":46,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12970735","id":"PMC_12970735","title":"MafA has strong cell transforming ability but is a weak transactivator.","date":"2003","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/12970735","citation_count":42,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25628604","id":"PMC_25628604","title":"Cooperation between HMGA1, PDX-1, and MafA is Essential for Glucose-Induced Insulin Transcription in Pancreatic Beta Cells.","date":"2015","source":"Frontiers in endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/25628604","citation_count":42,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22761608","id":"PMC_22761608","title":"Combined transfection of the three transcriptional factors, PDX-1, NeuroD1, and MafA, causes differentiation of bone marrow mesenchymal stem cells into insulin-producing cells.","date":"2012","source":"Experimental diabetes research","url":"https://pubmed.ncbi.nlm.nih.gov/22761608","citation_count":42,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34644565","id":"PMC_34644565","title":"Sex-biased islet β cell dysfunction is caused by the MODY MAFA S64F variant by inducing premature aging and senescence in males.","date":"2021","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/34644565","citation_count":41,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31980627","id":"PMC_31980627","title":"Kindlin-2 modulates MafA and β-catenin expression to regulate β-cell function and mass in mice.","date":"2020","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/31980627","citation_count":41,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18515495","id":"PMC_18515495","title":"MafA is a dedicated activator of the insulin gene in vivo.","date":"2008","source":"The Journal of endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/18515495","citation_count":40,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20584984","id":"PMC_20584984","title":"Islet beta-cell-specific MafA transcription requires the 5'-flanking conserved region 3 control domain.","date":"2010","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/20584984","citation_count":40,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22847061","id":"PMC_22847061","title":"Beta cell nuclear musculoaponeurotic fibrosarcoma oncogene family A (MafA) is deficient in type 2 diabetes.","date":"2012","source":"Diabetologia","url":"https://pubmed.ncbi.nlm.nih.gov/22847061","citation_count":40,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15963504","id":"PMC_15963504","title":"MafA transcription factor is phosphorylated by p38 MAP kinase.","date":"2005","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/15963504","citation_count":39,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19689288","id":"PMC_19689288","title":"Combination of MafA, PDX-1 and NeuroD is a useful tool to efficiently induce insulin-producing surrogate beta-cells.","date":"2009","source":"Current medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19689288","citation_count":39,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26207953","id":"PMC_26207953","title":"MAFA and T3 Drive Maturation of Both Fetal Human Islets and Insulin-Producing Cells Differentiated From hESC.","date":"2015","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/26207953","citation_count":39,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19029092","id":"PMC_19029092","title":"Sumoylation regulates the transcriptional activity of MafA in pancreatic beta cells.","date":"2008","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19029092","citation_count":39,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16505238","id":"PMC_16505238","title":"MafA expression and insulin promoter activity are induced by nicotinamide and related compounds in INS-1 pancreatic beta-cells.","date":"2006","source":"Diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/16505238","citation_count":39,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17449132","id":"PMC_17449132","title":"Role of PDX-1 and MafA as a potential therapeutic target for diabetes.","date":"2007","source":"Diabetes research and clinical practice","url":"https://pubmed.ncbi.nlm.nih.gov/17449132","citation_count":38,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19004825","id":"PMC_19004825","title":"The stability and transactivation potential of the mammalian MafA transcription factor are regulated by serine 65 phosphorylation.","date":"2008","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19004825","citation_count":37,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19393272","id":"PMC_19393272","title":"Role of MafA in pancreatic beta-cells.","date":"2009","source":"Advanced drug delivery reviews","url":"https://pubmed.ncbi.nlm.nih.gov/19393272","citation_count":36,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19407223","id":"PMC_19407223","title":"p38 MAPK is a major regulator of MafA protein stability under oxidative stress.","date":"2009","source":"Molecular endocrinology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/19407223","citation_count":36,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35562869","id":"PMC_35562869","title":"Role of the Transcription Factor MAFA in the Maintenance of Pancreatic β-Cells.","date":"2022","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/35562869","citation_count":35,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24312421","id":"PMC_24312421","title":"Reprogramming of various cell types to a beta-like state by Pdx1, Ngn3 and MafA.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24312421","citation_count":34,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12217400","id":"PMC_12217400","title":"An unusual inhibitory receptor--the mast cell function-associated antigen (MAFA).","date":"2002","source":"Molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/12217400","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8566088","id":"PMC_8566088","title":"Proximity relationships between the type I receptor for Fc epsilon (Fc epsilon RI) and the mast cell function-associated antigen (MAFA) studied by donor photobleaching fluorescence resonance energy transfer microscopy.","date":"1996","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/8566088","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18522939","id":"PMC_18522939","title":"MafA and MafB regulate Pdx1 transcription through the Area II control region in pancreatic beta cells.","date":"2008","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/18522939","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10744746","id":"PMC_10744746","title":"The RIPE3b1 activator of the insulin gene is composed of a protein(s) of approximately 43 kDa, whose DNA binding activity is inhibited by protein phosphatase treatment.","date":"2000","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10744746","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19576197","id":"PMC_19576197","title":"Expression of MafA in pancreatic progenitors is detrimental for pancreatic development.","date":"2009","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/19576197","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21278380","id":"PMC_21278380","title":"ATF2 interacts with beta-cell-enriched transcription factors, MafA, Pdx1, and beta2, and activates insulin gene transcription.","date":"2011","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/21278380","citation_count":30,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26904947","id":"PMC_26904947","title":"MafA-Controlled Nicotinic Receptor Expression Is Essential for Insulin Secretion and Is Impaired in Patients with Type 2 Diabetes.","date":"2016","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/26904947","citation_count":30,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35454124","id":"PMC_35454124","title":"MafA Regulation in β-Cells: From Transcriptional to Post-Translational Mechanisms.","date":"2022","source":"Biomolecules","url":"https://pubmed.ncbi.nlm.nih.gov/35454124","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20682694","id":"PMC_20682694","title":"Insulin transactivator MafA regulates intrathymic expression of insulin and affects susceptibility to type 1 diabetes.","date":"2010","source":"Diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/20682694","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33631146","id":"PMC_33631146","title":"The MafA-target gene PPP1R1A regulates GLP1R-mediated amplification of glucose-stimulated insulin secretion in β-cells.","date":"2021","source":"Metabolism: clinical and experimental","url":"https://pubmed.ncbi.nlm.nih.gov/33631146","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22776709","id":"PMC_22776709","title":"The combined expression of Pdx1 and MafA with either Ngn3 or NeuroD improves the differentiation efficiency of mouse embryonic stem cells into insulin-producing cells.","date":"2012","source":"Cell transplantation","url":"https://pubmed.ncbi.nlm.nih.gov/22776709","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16934222","id":"PMC_16934222","title":"MafA differentiates rat intestinal cells into insulin-producing cells.","date":"2006","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/16934222","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27187823","id":"PMC_27187823","title":"Reprogramming of Pancreatic Exocrine Cells AR42J Into Insulin-producing Cells Using mRNAs for Pdx1, Ngn3, and MafA Transcription Factors.","date":"2016","source":"Molecular therapy. Nucleic acids","url":"https://pubmed.ncbi.nlm.nih.gov/27187823","citation_count":27,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20158571","id":"PMC_20158571","title":"MafA promotes the reprogramming of placenta-derived multipotent stem cells into pancreatic islets-like and insulin+ cells.","date":"2011","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/20158571","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21646385","id":"PMC_21646385","title":"Proteasome activator PA28{gamma} stimulates degradation of GSK3-phosphorylated insulin transcription activator MAFA.","date":"2011","source":"Journal of molecular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/21646385","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17583797","id":"PMC_17583797","title":"Inhibition of MafA transcriptional activity and human insulin gene transcription by interleukin-1beta and mitogen-activated protein kinase kinase kinase in pancreatic islet beta cells.","date":"2007","source":"Diabetologia","url":"https://pubmed.ncbi.nlm.nih.gov/17583797","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20208071","id":"PMC_20208071","title":"Phosphorylation within the MafA N terminus regulates C-terminal dimerization and DNA binding.","date":"2010","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/20208071","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19624757","id":"PMC_19624757","title":"Neither MafA/L-Maf nor MafB is essential for lens development in mice.","date":"2009","source":"Genes to cells : devoted to molecular & cellular mechanisms","url":"https://pubmed.ncbi.nlm.nih.gov/19624757","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12008030","id":"PMC_12008030","title":"Clustering the mast cell function-associated antigen (MAFA) leads to tyrosine phosphorylation of p62Dok and SHIP and affects RBL-2H3 cell cycle.","date":"2002","source":"Immunology letters","url":"https://pubmed.ncbi.nlm.nih.gov/12008030","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30911681","id":"PMC_30911681","title":"The calcium channel subunit gamma-4 is regulated by MafA and necessary for pancreatic beta-cell specification.","date":"2019","source":"Communications biology","url":"https://pubmed.ncbi.nlm.nih.gov/30911681","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17239820","id":"PMC_17239820","title":"Islet cell differentiation in liver by combinatorial expression of transcription factors neurogenin-3, BETA2, and RIPE3b1.","date":"2007","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/17239820","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22476346","id":"PMC_22476346","title":"Expedient chemical synthesis of 75mer DNA binding domain of MafA: an insight on its binding to insulin enhancer.","date":"2012","source":"Amino acids","url":"https://pubmed.ncbi.nlm.nih.gov/22476346","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23660596","id":"PMC_23660596","title":"Preventing p38 MAPK-mediated MafA degradation ameliorates β-cell dysfunction under oxidative stress.","date":"2013","source":"Molecular endocrinology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/23660596","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19937015","id":"PMC_19937015","title":"Definition of Mafa-A and -B haplotypes in pedigreed cynomolgus macaques (Macaca fascicularis).","date":"2009","source":"Immunogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/19937015","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31822804","id":"PMC_31822804","title":"Transcriptome analysis of human brain microvascular endothelial cells response to Neisseria meningitidis and its antigen MafA using RNA-seq.","date":"2019","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/31822804","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35872977","id":"PMC_35872977","title":"The m6A Methyltransferase METTL3 Ameliorates Methylglyoxal-Induced Impairment of Insulin Secretion in Pancreatic β Cells by Regulating MafA Expression.","date":"2022","source":"Frontiers in endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/35872977","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24260156","id":"PMC_24260156","title":"Generation of functional insulin-producing cells from neonatal porcine liver-derived cells by PDX1/VP16, BETA2/NeuroD and MafA.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24260156","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25126749","id":"PMC_25126749","title":"MafA is required for postnatal proliferation of pancreatic β-cells.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/25126749","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22623997","id":"PMC_22623997","title":"Memory immune responses against pandemic (H1N1) 2009 influenza virus induced by a whole particle vaccine in cynomolgus monkeys carrying Mafa-A1*052:02.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22623997","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31208980","id":"PMC_31208980","title":"MafB Is Important for Pancreatic β-Cell Maintenance under a MafA-Deficient Condition.","date":"2019","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/31208980","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24794627","id":"PMC_24794627","title":"Differentiation of iPSCs into insulin-producing cells via adenoviral transfection of PDX-1, NeuroD1 and MafA.","date":"2014","source":"Diabetes research and clinical practice","url":"https://pubmed.ncbi.nlm.nih.gov/24794627","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26546820","id":"PMC_26546820","title":"Islet-specific monoamine oxidase A and B expression depends on MafA transcriptional activity and is compromised in type 2 diabetes.","date":"2015","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/26546820","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24013263","id":"PMC_24013263","title":"Both PAX4 and MAFA are expressed in a substantial proportion of normal human pancreatic alpha cells and deregulated in patients with type 2 diabetes.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24013263","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20718938","id":"PMC_20718938","title":"SUMOylation negatively regulates transcriptional and oncogenic activities of MafA.","date":"2010","source":"Genes to cells : devoted to molecular & cellular mechanisms","url":"https://pubmed.ncbi.nlm.nih.gov/20718938","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16189514","id":"PMC_16189514","title":"Towards a proteome-scale map of the human protein-protein interaction network.","date":"2005","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/16189514","citation_count":2090,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12477932","id":"PMC_12477932","title":"Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12477932","citation_count":1479,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"25416956","id":"PMC_25416956","title":"A proteome-scale map of the human interactome network.","date":"2014","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/25416956","citation_count":977,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"32296183","id":"PMC_32296183","title":"A reference map of the human binary protein interactome.","date":"2020","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/32296183","citation_count":849,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21873635","id":"PMC_21873635","title":"Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium.","date":"2011","source":"Briefings in bioinformatics","url":"https://pubmed.ncbi.nlm.nih.gov/21873635","citation_count":656,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12393723","id":"PMC_12393723","title":"Lack of proliferative capacity of human effector and memory T cells expressing killer cell lectinlike receptor G1 (KLRG1).","date":"2002","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/12393723","citation_count":270,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19406987","id":"PMC_19406987","title":"KLRG1 signaling induces defective Akt (ser473) phosphorylation and proliferative dysfunction of highly differentiated CD8+ T cells.","date":"2009","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/19406987","citation_count":207,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16461340","id":"PMC_16461340","title":"Killer cell lectin-like receptor G1 binds three members of the classical cadherin family to inhibit NK cell cytotoxicity.","date":"2006","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/16461340","citation_count":194,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15879103","id":"PMC_15879103","title":"Expression of killer cell lectin-like receptor G1 on antigen-specific human CD8+ T lymphocytes during active, latent, and resolved infection and its relation with CD57.","date":"2005","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/15879103","citation_count":145,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16140789","id":"PMC_16140789","title":"Increased expression of the NK cell receptor KLRG1 by virus-specific CD8 T cells during persistent antigen stimulation.","date":"2005","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/16140789","citation_count":130,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"20379614","id":"PMC_20379614","title":"Personalized smoking cessation: interactions between nicotine dose, dependence and quit-success genotype score.","date":"2010","source":"Molecular medicine (Cambridge, Mass.)","url":"https://pubmed.ncbi.nlm.nih.gov/20379614","citation_count":108,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"31326977","id":"PMC_31326977","title":"Highly differentiated cytotoxic T cells in inclusion body myositis.","date":"2019","source":"Brain : a journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/31326977","citation_count":91,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"17079288","id":"PMC_17079288","title":"Analysis of CD127 and KLRG1 expression on hepatitis C virus-specific CD8+ T cells reveals the existence of different memory T-cell subsets in the peripheral blood and liver.","date":"2006","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/17079288","citation_count":87,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"27566818","id":"PMC_27566818","title":"Killer Cell Lectin-like Receptor G1 Inhibits NK Cell Function through Activation of Adenosine 5'-Monophosphate-Activated Protein Kinase.","date":"2016","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/27566818","citation_count":86,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19604491","id":"PMC_19604491","title":"Structure of natural killer cell receptor KLRG1 bound to E-cadherin reveals basis for MHC-independent missing self recognition.","date":"2009","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/19604491","citation_count":84,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"32814053","id":"PMC_32814053","title":"Interactome Mapping Provides a Network of Neurodegenerative Disease Proteins and Uncovers Widespread Protein Aggregation in Affected Brains.","date":"2020","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/32814053","citation_count":79,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"32954948","id":"PMC_32954948","title":"An atlas of immune cell exhaustion in HIV-infected individuals revealed by single-cell transcriptomics.","date":"2020","source":"Emerging microbes & infections","url":"https://pubmed.ncbi.nlm.nih.gov/32954948","citation_count":78,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"20394788","id":"PMC_20394788","title":"Variation of human natural killer cell phenotypes with age: identification of a unique KLRG1-negative subset.","date":"2010","source":"Human immunology","url":"https://pubmed.ncbi.nlm.nih.gov/20394788","citation_count":75,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"20237496","id":"PMC_20237496","title":"New genetic associations detected in a host response study to hepatitis B vaccine.","date":"2010","source":"Genes and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/20237496","citation_count":69,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"9862378","id":"PMC_9862378","title":"2F1 antigen, the mouse homolog of the rat \"mast cell function-associated antigen\", is a lectin-like type II transmembrane receptor expressed by natural killer cells.","date":"1998","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/9862378","citation_count":62,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"23966413","id":"PMC_23966413","title":"KLRG1 negatively regulates natural killer cell functions through the Akt pathway in individuals with chronic hepatitis C virus infection.","date":"2013","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/23966413","citation_count":56,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"17213182","id":"PMC_17213182","title":"Identification of genes related to Parkinson's disease using expressed sequence tags.","date":"2007","source":"DNA research : an international journal for rapid publication of reports on genes and genomes","url":"https://pubmed.ncbi.nlm.nih.gov/17213182","citation_count":55,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15368283","id":"PMC_15368283","title":"Frequent expression of the natural killer cell receptor KLRG1 in human cord blood T cells: correlation with replicative history.","date":"2004","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/15368283","citation_count":53,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"17617594","id":"PMC_17617594","title":"Tumor-associated E-cadherin mutations affect binding to the killer cell lectin-like receptor G1 in humans.","date":"2007","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/17617594","citation_count":53,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"32477365","id":"PMC_32477365","title":"KLRG1 and CD103 Expressions Define Distinct Intestinal Tissue-Resident Memory CD8 T Cell Subsets Modulated in Crohn's Disease.","date":"2020","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/32477365","citation_count":52,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"29197680","id":"PMC_29197680","title":"Increased Coexpression of PD-1, TIGIT, and KLRG-1 on Tumor-Reactive CD8+ T Cells During Relapse after Allogeneic Stem Cell Transplantation.","date":"2017","source":"Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation","url":"https://pubmed.ncbi.nlm.nih.gov/29197680","citation_count":51,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"30905683","id":"PMC_30905683","title":"KLRG1+ natural killer cells exert a novel antifibrotic function in chronic hepatitis B.","date":"2019","source":"Journal of hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/30905683","citation_count":46,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"23740233","id":"PMC_23740233","title":"Senescence marker killer cell lectin-like receptor G1 (KLRG1) contributes to TNF-α production by interaction with its soluble E-cadherin ligand in chronically inflamed joints.","date":"2013","source":"Annals of the rheumatic diseases","url":"https://pubmed.ncbi.nlm.nih.gov/23740233","citation_count":40,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"1831652","id":"PMC_1831652","title":"Possible interactions between the Fc epsilon receptor and a novel mast cell function-associated antigen.","date":"1991","source":"International immunology","url":"https://pubmed.ncbi.nlm.nih.gov/1831652","citation_count":39,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"24337749","id":"PMC_24337749","title":"KLRG1 impairs CD4+ T cell responses via p16ink4a and p27kip1 pathways: role in hepatitis B vaccine failure in individuals with hepatitis C virus infection.","date":"2013","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/24337749","citation_count":39,"is_preprint":false,"source_track":"gene2pubmed"}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":46376,"output_tokens":8908,"usd":0.136374},"stage2":{"model":"claude-opus-4-6","input_tokens":12844,"output_tokens":4848,"usd":0.27813},"total_usd":0.737607,"stage1_batch_id":"msgbatch_01Mgbec4vM6c9vXht7JVJzss","stage2_batch_id":"msgbatch_01JkuuH5RB2BdJNsgnhjbC6s","note":"batch pricing = 50% of standard","round2_stage1":{"model":"claude-sonnet-4-6","input_tokens":60452,"output_tokens":13308,"usd":0.190488},"round2_rules_fired":"R3","round2_stage2":{"model":"claude-opus-4-6","input_tokens":17157,"output_tokens":105,"usd":0.132615}},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2002,\n      \"finding\": \"MafA (mammalian homologue of avian MafA/L-Maf) was identified as the RIPE3b1 transcription factor that specifically binds the insulin gene enhancer element RIPE3b and activates insulin gene expression; it is selectively expressed in pancreatic beta cells but not alpha cells.\",\n      \"method\": \"Biochemical purification of RIPE3b1, cloning of human mafA, electrophoretic mobility shift assay (EMSA), reporter assays\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — biochemical purification plus functional validation; foundational identification paper replicated in same year by independent group\",\n      \"pmids\": [\"12011435\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"MafA is a glucose-regulated transcriptional activator of the insulin gene that binds the RIPE3b/C1 element; MafA mRNA and protein are up-regulated by glucose, and a dominant-negative form of MafA inhibited insulin promoter activity.\",\n      \"method\": \"RT-PCR, EMSA, transient luciferase reporter assays, dominant-negative overexpression\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — multiple orthogonal methods in same study; independently replicated\",\n      \"pmids\": [\"12368292\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"MafA physically interacts with endogenous PDX-1 and BETA2, and this interaction is required for synergistic activation of the insulin promoter; dominant-negative MafA and siRNA knockdown profoundly reduce insulin promoter activity in beta cell lines.\",\n      \"method\": \"Co-immunoprecipitation, GST pull-down, siRNA knockdown, reporter assays, adenoviral overexpression\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — reciprocal Co-IP + GST pull-down + functional reporter assays + adenoviral expression in islets\",\n      \"pmids\": [\"15665000\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"MafA-deficient mice display glucose intolerance and diabetes with severely impaired glucose-, arginine-, and KCl-stimulated insulin secretion; MafA regulates insulin 1, insulin 2, Pdx1, Beta2, and Glut-2 transcript levels in vivo.\",\n      \"method\": \"Targeted gene knockout in mice, glucose tolerance tests, insulin secretion assays, RT-PCR\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean KO with defined metabolic and molecular phenotype\",\n      \"pmids\": [\"15923615\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"FoxO1 protects beta cells against oxidative stress by forming a complex with Pml and Sirt1 to activate MafA (and NeuroD) expression; hyperglycemia suppresses MafA expression in vivo, and this is prevented by constitutively nuclear FoxO1 transgene.\",\n      \"method\": \"Complex formation (Co-IP), acetylation-defective mutants, transgenic mouse model, in vivo glucose challenge\",\n      \"journal\": \"Cell metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — epistasis established by transgenic rescue + Co-IP complex identification + mutant analysis\",\n      \"pmids\": [\"16154098\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"MafA is phosphorylated at serines 14 and 65 by ERK2 in vitro; mutation of these residues to alanine severely impairs MafA transcriptional activity and its ability to induce lens differentiation/NR-specific target gene expression.\",\n      \"method\": \"In vitro kinase assays with ERK2, p38, JNK, ERK5; site-directed mutagenesis; reporter assays; in ovo transdifferentiation assay\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro kinase assay plus mutagenesis plus functional readout\",\n      \"pmids\": [\"11416124\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"MafA protein stability in beta cells is regulated by glucose through constitutive phosphorylation by glycogen synthase kinase 3 (GSK3) at multiple N-terminal sites; GSK3 phosphorylation is a prerequisite for rapid MafA degradation under low-glucose conditions.\",\n      \"method\": \"Pharmacological GSK3 inhibition in MIN6 cells, mutational analysis of phosphorylation sites, pulse-chase protein stability assays\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — mutagenesis + pharmacological inhibition + stability assays; replicates prior phosphorylation work\",\n      \"pmids\": [\"17682063\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Phosphorylation at Ser65 of mammalian MafA regulates both protein stability and transactivation potential; Ser65 phosphorylation is the initial degradation signal, with subsequent ubiquitinylation occurring in the C terminus (aa 234–359); phosphorylation at Ser14 enhances activation without affecting protein turnover.\",\n      \"method\": \"Phosphomimetic and phosphoablative mutagenesis, ubiquitination assays, SDS-PAGE mobility shift, deletion constructs\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstitution with mutagenesis and ubiquitination assays\",\n      \"pmids\": [\"19004825\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Sumoylation of MafA at Lys32 negatively regulates its transcriptional activity toward the insulin gene promoter; low glucose or H2O2 increases endogenous MafA sumoylation; sumoylation does not affect nuclear localization or ubiquitin-dependent degradation of MafA.\",\n      \"method\": \"In-cell sumoylation assays, mutagenesis (K32R), reporter assays, subcellular localization imaging\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — identification of modification site by mutagenesis + functional reporter assays + localization assessment\",\n      \"pmids\": [\"19029092\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"MafA phosphorylation by p38 MAP kinase occurs at Thr113, Thr57, and Ser272 (identified by mass spectrometry and western blot); mutation of these residues severely impairs MafA biological activity.\",\n      \"method\": \"In vitro kinase assay, mass spectrometry, western blot, mutagenesis\",\n      \"journal\": \"FEBS letters\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro kinase assay + mass spectrometry identification of sites + mutagenesis functional validation\",\n      \"pmids\": [\"15963504\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"p38 MAPK is a major regulator of MafA protein stability under oxidative stress; p38 MAPK and GSK3 both regulate MafA stability, but only p38 MAPK inhibition prevents oxidative-stress-dependent MafA degradation; simultaneous mutation of Thr57 and Thr134 to alanine prevents p38-mediated degradation.\",\n      \"method\": \"Pharmacological inhibitors, mutagenesis, protein stability assays in MIN6 cells and isolated mouse islets\",\n      \"journal\": \"Molecular endocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — mutagenesis + pharmacological epistasis + cell and islet experiments\",\n      \"pmids\": [\"19407223\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Phosphorylation within the MafA N-terminal transactivation domain (aa 1–72) is required for C-terminal dimerization and DNA binding; dephosphorylation precludes MafA dimer formation and dramatically reduces DNA-binding ability, whereas MafB DNA binding is phosphorylation-independent.\",\n      \"method\": \"Mass spectrometry identification of phosphorylation sites, dephosphorylation assays, MafA/B chimeras, EMSA\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — mass spectrometry + chimeric protein analysis + EMSA\",\n      \"pmids\": [\"20208071\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"PA28γ (proteasome activator) binds GSK3-phosphorylated MafA and stimulates its proteasomal degradation, thereby attenuating MafA-driven insulin promoter transcription; alanine substitutions at GSK3 phosphorylation sites prevent PA28γ binding and resistance to degradation.\",\n      \"method\": \"Co-immunoprecipitation of PA28γ with MafA, mutagenesis of phosphorylation sites, reporter assays, proteasome inhibition\",\n      \"journal\": \"Journal of molecular endocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — Co-IP + mutagenesis + proteasome functional assay\",\n      \"pmids\": [\"21646385\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"SUMOylation at a conserved lysine residue in the MafA N-terminal transactivator domain negatively regulates its transcriptional and oncogenic (cell-transforming) activities; a K32R SUMOylation-deficient mutant shows enhanced transactivation of insulin and crystallin promoters and enhanced colony formation.\",\n      \"method\": \"Mutagenesis (K32R), reporter assays, in ovo electroporation, colony formation assay\",\n      \"journal\": \"Genes to cells\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — site-specific mutagenesis + multiple functional readouts\",\n      \"pmids\": [\"20718938\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Beta-cell-specific MafA transcription is principally controlled by a conserved region 3 (bp −8118 to −7750) of the mafA promoter; FoxA2, Nkx2.2, and PDX-1 directly bind this region in vivo and mediate its activation; siRNA knockdown of PDX-1 decreases mafA mRNA in beta cell lines.\",\n      \"method\": \"Chromatin immunoprecipitation (ChIP), mutational analysis of conserved regions, cell-line reporter assays, siRNA knockdown, Nkx2.2-null mouse model\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — ChIP + mutagenesis + siRNA + in vivo null mouse; multiple labs confirmed upstream regulators\",\n      \"pmids\": [\"16847327\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"MafA regulates a broad set of beta cell genes beyond insulin, including Glut2, PDX1, Nkx6-1, GLP1R, Pcsk1, and pyruvate carboxylase; MafA overproduction enhances and dominant-negative MafA diminishes binding to the insulin promoter and glucose-stimulated insulin secretion in stable INS-1 cell lines.\",\n      \"method\": \"Inducible stable cell lines (overexpression/dominant-negative), EMSA, RT-PCR, insulin secretion assays\",\n      \"journal\": \"Diabetologia\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — stable inducible cell lines with multiple orthogonal readouts\",\n      \"pmids\": [\"17149590\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"The RIPE3b1/MafA transcription factor stimulates the Area II region of the pdx-1 gene by binding to sequence blocks 4 and 5 (B4/5); the large Maf protein comprising RIPE3b1 was shown by ChIP to occupy the Area II region of the endogenous pdx-1 gene in beta cells.\",\n      \"method\": \"EMSA, chromatin immunoprecipitation, mutagenesis, reporter assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — ChIP + EMSA + mutagenesis demonstrating MafA directly regulates pdx-1\",\n      \"pmids\": [\"12551916\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"MafA and MafB regulate beta-cell-enriched Pdx1 expression exclusively through the Area II control domain; in adult beta cells, only MafA is bound to Area II (by ChIP); MafB binds Area II during embryonic development and is required for Pdx1 expression during beta-cell formation.\",\n      \"method\": \"Quantitative ChIP, cell-line transfection reporter assays, MafB-null mouse transgene analysis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — quantitative ChIP + reporter assays + in vivo mouse model\",\n      \"pmids\": [\"18522939\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"MafA physically associates with the ~1.5 MDa MLL3 and MLL4 histone H3K4 methyltransferase complexes in beta cell extracts; knockdown of NCOA6 (core subunit of these complexes) reduces expression of a subset of MafA target genes in mouse and human beta cell lines.\",\n      \"method\": \"Unbiased in-cell biochemistry + mass spectrometry, size-fractionation, Co-IP, NCOA6 knockdown in cell lines and conditional KO in mice\",\n      \"journal\": \"Diabetes\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — mass spectrometry interactome + reciprocal Co-IP + conditional KO with gene expression phenotype\",\n      \"pmids\": [\"26180087\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"A missense MAFA mutation (p.Ser64Phe) impairs phosphorylation within the transactivation domain, profoundly increases MAFA protein stability under both high and low glucose conditions, and enhances transactivation potential in beta cell lines; this causes familial insulinomatosis or diabetes.\",\n      \"method\": \"Exome sequencing (disease variant identification), beta-cell line functional assays (protein stability, transactivation), mutant characterization\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — human disease variant functionally characterized in beta cell lines with protein stability and transactivation readouts; replicated in two families\",\n      \"pmids\": [\"29339498\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Glucose induces MafA expression in pancreatic beta cell lines via the hexosamine biosynthetic pathway; glucosamine mimics glucose induction of MafA, inhibition of the hexosamine pathway abolishes MafA induction by high glucose, and O-GlcNAc transferase (OGT) is required for glucose-dependent MafA expression.\",\n      \"method\": \"Pharmacological inhibitors of hexosamine pathway, glucosamine supplementation, OGT expression manipulation, RT-PCR/western blot\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple pharmacological interventions + enzyme expression manipulation defining pathway\",\n      \"pmids\": [\"17142462\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Thyroid hormone (T3) directly binds to the Mafa promoter via thyroid hormone receptor (confirmed by ChIP and EMSA) and activates Mafa transcription; T3-induced functional maturation of beta cells (glucose-responsive insulin secretion) was abolished by dominant-negative Mafa.\",\n      \"method\": \"ChIP, EMSA, luciferase reporter, dominant-negative Mafa, in vivo neonatal T3 supplementation/inhibition\",\n      \"journal\": \"Diabetes\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — direct receptor-DNA interaction confirmed by ChIP + EMSA + reporter + in vivo epistasis\",\n      \"pmids\": [\"23305647\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"ATF2 forms a complex with MafA and acquires DNA-binding capacity to the C1/RIPE3b element only upon complex formation; ATF2 also interacts with Pdx1 and Beta2, and co-expression of all four factors synergistically activates the insulin promoter; knockdown of MafA or ATF2 decreases endogenous insulin mRNA.\",\n      \"method\": \"Co-IP, EMSA (complex formation), siRNA knockdown, reporter assays, immunohistochemistry\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — Co-IP + EMSA + siRNA with multiple functional readouts\",\n      \"pmids\": [\"21278380\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"HMGA1 physically interacts with PDX-1 and MafA both in vitro and in vivo; HMGA1 overexpression enhances the transactivating activity of PDX-1 and MafA on insulin promoters, while HMGA1 knockdown decreases this activity; high glucose increases HMGA1 binding to the insulin promoter.\",\n      \"method\": \"Co-IP, GST pull-down, ChIP, reporter assays, siRNA knockdown and overexpression\",\n      \"journal\": \"Frontiers in endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — Co-IP + ChIP + reporter; single lab\",\n      \"pmids\": [\"25628604\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"MafA transcriptionally activates nicotinic receptor genes (ChrnB2, ChrnB4) and adrenergic receptor gene (Adra2A) in beta cells; MafA-deficient mice have impaired acetylcholine-mediated insulin secretion via nicotinic signaling, establishing MafA as a regulator of autonomic nervous system-mediated insulin secretion.\",\n      \"method\": \"MafA-deficient mouse model, ChIP, reporter assays, insulin secretion assays with nicotinic agonists/antagonists\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — ChIP + KO mouse + functional secretion assays + reporter assays\",\n      \"pmids\": [\"26904947\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"MafA transcriptionally controls CaVγ4 (CACNG4) expression in beta cells (verified by ChIP and MafA beta-cell-specific KO); loss of CaVγ4 reduces L-type Ca2+ channel expression and voltage-gated Ca2+ entry, thereby suppressing glucose-stimulated insulin exocytosis.\",\n      \"method\": \"ChIP, MafA beta-cell-specific KO mice, Ca2+ imaging, insulin secretion assays\",\n      \"journal\": \"Communications biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — ChIP + conditional KO + functional Ca2+ and secretion assays\",\n      \"pmids\": [\"30911681\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"MafA transcriptionally activates MaoA and MaoB (monoamine oxidase) genes in beta cells; biochemical studies showed direct MafA binding to MaoA and MaoB transcriptional control sequences; MaoB expression is reduced in MafA-deficient beta cells and in type 2 diabetic mouse and human islets.\",\n      \"method\": \"ChIP/reporter assays showing direct MafA binding, MafA-deficient mouse model, human T2D islet immunostaining\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct binding assays + KO model; single lab\",\n      \"pmids\": [\"26546820\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Kindlin-2 binds to and stabilizes MafA protein through its C-terminal region; Kindlin-2 deletion causes reduced MafA protein levels, impaired insulin secretion, and reduced beta-cell proliferation and mass in mice.\",\n      \"method\": \"Co-IP (Kindlin-2 C-terminal domain binding to MafA), conditional KO in mice, Ca2+ imaging, beta-cell proliferation assays\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — Co-IP domain mapping + conditional KO with multiple defined phenotypes\",\n      \"pmids\": [\"31980627\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"The MAFA S64F mutation causes sex-biased islet aging: heterozygous male MafAS64F/+ mice show transiently higher MafA protein levels preceding glucose intolerance; male but not female beta cells show sex-dependent changes to Ca2+ signaling, DNA damage, aging/senescence genes; MAFAS64F in male human beta cells accelerates cellular senescence and increases senescence-associated secretory proteins.\",\n      \"method\": \"S64F knock-in mouse model, glucose tolerance tests, transcriptomics, human beta cell line senescence assays\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — disease knock-in model + human cell validation + multiple orthogonal readouts\",\n      \"pmids\": [\"34644565\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"MafA expression in pancreatic progenitors (Pdx1+ cells) reduces pancreatic mass and progenitor proliferation via induction of cyclin kinase inhibitors p27 and p57; MafA expression in Pdx1+ cells until E12.5 is sufficient to inhibit endocrine cell formation.\",\n      \"method\": \"Conditional transgenic MafA expression in Pdx1+ progenitors, cell cycle analysis, immunohistochemistry\",\n      \"journal\": \"Developmental biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — transgenic gain-of-function with defined molecular mechanism (p27/p57 induction)\",\n      \"pmids\": [\"19576197\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"MafA is required for postnatal beta-cell proliferation; MafA transcriptionally activates the prolactin receptor (Prlr) promoter, which drives cyclin D2 (Ccnd2) expression; loss of MafA impairs beta-cell replication at 4 weeks via the prolactin/Jak2/Stat5B/cyclin D2 axis.\",\n      \"method\": \"MafA KO mice, transcriptome analysis, Prlr promoter reporter assay, prolactin stimulation, Stat5B phosphorylation assays\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — KO mouse + reporter + signaling assays placing MafA in proliferation pathway\",\n      \"pmids\": [\"25126749\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"MafA controls the beta-cell-specific transcription of mafA through the region 3 (R3) cis-domain in cooperation with Nkx6.1 and Pax6, which bind to R3 in ChIP assays and activate MafA in gel shift and transfection assays; Pax6 and Pdx-1 also bind to R1 and R6 regions; R3 is necessary for glucose-induced MafA expression.\",\n      \"method\": \"Transgenic reporter mice (R3, R1-6, R1-6ΔR3), ChIP, EMSA, transfection assays, Nkx6.1/Pax6 KO mouse models\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — transgenic reporters + ChIP + EMSA + in vivo KO validation; multiple orthogonal methods\",\n      \"pmids\": [\"20584984\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"lncRNA Meg3 epigenetically regulates MafA expression: Meg3 binds EZH2 (PRC2 methyltransferase), promoting H3K27 trimethylation of Rad21, Smc3, and Sin3α promoters; Rad21, Smc3, and Sin3α directly repress the MafA promoter, and their inhibition upregulates MafA and insulin in beta cells.\",\n      \"method\": \"ChIP-qPCR, RNA immunoprecipitation, Ezh2/Meg3 siRNA knockdown, western blot, RT-PCR in MIN6 cells and mouse islets\",\n      \"journal\": \"Cellular physiology and biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP + RIP + siRNA; single lab study\",\n      \"pmids\": [\"29529600\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"METTL3-mediated m6A methylation regulates MafA mRNA stability; METTL3 silencing reduces m6A levels and MafA mRNA stability/expression, impairing glucose-stimulated insulin secretion; MafA overexpression rescues the secretion defect caused by METTL3 silencing.\",\n      \"method\": \"METTL3 siRNA knockdown, m6A measurement, mRNA stability assays, MafA overexpression rescue, insulin secretion assays in NIT-1/β-TC-6 cells\",\n      \"journal\": \"Frontiers in endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic pathway placed by knockdown + rescue; single lab\",\n      \"pmids\": [\"35872977\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"miR-30d increases MafA expression by targeting MAP4K4, a TNF-α-activated kinase; overexpression of miR-30d prevents TNF-α-induced reduction of MafA and insulin receptor substrate 2 (IRS2), protecting insulin transcription and secretion in beta cells.\",\n      \"method\": \"miR-30d overexpression, MAP4K4 target validation, insulin secretion assays, western blot in MIN6/INS-1 cells and db/db mouse islets\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct target validation + functional rescue assays; single lab\",\n      \"pmids\": [\"22733810\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Low-threshold mechanoreceptor (LTM) neurons in dorsal root ganglia express MafA; in MafA mutant mice, a discrete subset of LTMs display altered expression of neurotrophic factor receptors; MafA is genetically downstream of Ret signaling for LTM specification.\",\n      \"method\": \"MafA-null mouse model, immunohistochemistry, in situ hybridization, genetic epistasis with Ret knockout\",\n      \"journal\": \"Neuron\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis in KO mouse models with defined cellular phenotype in sensory neurons\",\n      \"pmids\": [\"20064392\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Loss of MafA in beta cells leads to dedifferentiation: reduced/lost insulin expression in most beta cells, minority converted to glucagon-expressing cells; upregulation of endocrine progenitor markers observed in MafA KO islets; in db/db and STZ diabetic mice, compromised beta cells dedifferentiate with re-expression of MafB.\",\n      \"method\": \"MafA KO mice, lineage tracing, immunofluorescence, gene expression profiling\",\n      \"journal\": \"Diabetologia\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — lineage tracing + KO + disease models; multiple orthogonal methods\",\n      \"pmids\": [\"25500951\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"MafA transcriptionally activates PPP1R1A (protein phosphatase 1 inhibitor 1A) in beta cells; reduced PPP1R1A impairs GLP-1-mediated amplification of glucose-stimulated insulin secretion and PKA-target protein phosphorylation; PPP1R1A mRNA levels strongly correlate with MAFA in human islets.\",\n      \"method\": \"MafA KO mouse/knockdown, PPP1R1A siRNA, reporter assays, insulin secretion assays, PKA phosphorylation assays\",\n      \"journal\": \"Metabolism: clinical and experimental\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — KO + siRNA + reporter + functional assays; single lab\",\n      \"pmids\": [\"33631146\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"MafA cell-transforming activity is stronger than its transactivation activity; the transforming ability maps to the MafA DNA-binding domain (by chimeric analysis with MafB); phosphorylation at two conserved serines in the transactivation domain controls both transactivation and transformation; MafA-ER fusion proteins show hormone-dependent transformation.\",\n      \"method\": \"Chicken embryo fibroblast transformation assay, MafA/MafB chimeric protein analysis, site-directed mutagenesis, MafA-estrogen receptor fusion\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — domain mapping by chimeras + mutagenesis + inducible fusion system\",\n      \"pmids\": [\"12970735\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"c-Jun is upregulated by ROS in diabetic islets and suppresses MafA expression; adenoviral overexpression of c-Jun in MIN6 cells and isolated islets significantly decreased MafA expression and insulin promoter activity; MafA overexpression restored insulin promoter activity suppressed by c-Jun.\",\n      \"method\": \"db/db mouse model, adenoviral c-Jun overexpression, MafA overexpression rescue, western blot, reporter assays\",\n      \"journal\": \"Diabetes\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — adenoviral gain-of-function + rescue; single lab\",\n      \"pmids\": [\"20424231\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"MAFA is a beta-cell-enriched basic leucine zipper (bZIP) transcription factor that binds the RIPE3b/C1 element of the insulin gene promoter to activate insulin transcription in a glucose-responsive manner; it synergizes with PDX-1 and BETA2 (NeuroD) through direct protein–protein interactions, recruits MLL3/MLL4 histone methyltransferase complexes, and also transcriptionally drives a broad beta-cell gene program (Glut2, GLP1R, Pcsk1, nicotinic receptors, CaVγ4, MaoA/B, PPP1R1A, prolactin receptor) that together control glucose sensing, insulin secretion, and beta-cell mass; its protein levels are tightly regulated post-translationally by phosphorylation (via GSK3, p38 MAPK, and ERK2) controlling proteasomal degradation, by SUMOylation at Lys32 that attenuates activity, and by PA28γ-mediated proteasomal targeting; upstream, MafA transcription is controlled by FoxO1–Pml–Sirt1, thyroid hormone receptor, PDX-1/FoxA2/Nkx2.2/Nkx6.1/Pax6 acting on a conserved region 3 of the MafA promoter, and by Kindlin-2-mediated protein stabilization; loss of MafA causes beta-cell dedifferentiation and diabetes, while hyperstabilizing mutations (e.g., S64F) cause insulinomatosis or sex-biased diabetes through accelerated senescence.\"\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\nI'll systematically classify papers before extracting discoveries.\n\n**Classification:**\n\nThe query gene is MAFA (MAF bZIP Transcription Factor A, the pancreatic β-cell transcription factor / also expressed in neural/retinal contexts).\n\n**EXCLUDE cases:**\n- Papers [23], [32], [45] (mAFA = mobile Atrial Fibrillation App — alias collision, clinical trial)\n- Papers [33], [46], [67], [68], [85] — rat/human MAFA = \"Mast Cell Function-Associated Antigen\" (KLRG1 homolog) — alias collision, completely different protein\n- Paper [90] — Mafa-A/B = MHC class I genes in cynomolgus macaques — alias collision\n- Paper [91] — MafA of Neisseria meningitidis (bacterial adhesin) — symbol collision, non-orthologous organism\n- Paper [95] — Mafa-A1*052:02 = MHC allele in macaques — alias collision\n- Additional curated papers [6],[7],[8],[9],[10],[12],[13],[14],[15],[17],[18],[19],[20],[21],[23],[24],[25],[26],[27],[28],[29],[30] — all about KLRG1 (killer cell lectin-like receptor G1), which is the mouse/human homolog of rat MAFA (mast cell function-associated antigen) — alias collision\n- Additional curated papers [1],[2],[3],[4],[5],[16],[22] — generic interactome/proteome/EST studies not specific to MAFA\n- Additional curated paper [11] — smoking cessation genetics, not MAFA\n\n**KEEP:** Papers [1]-[22], [24]-[32], [34]-[44], [47]-[66], [69]-[84], [86]-[89], [92]-[94], [96]-[100] that describe the canonical pancreatic/neural MAFA transcription factor.\n\nLet me now extract mechanistic discoveries from KEPT papers.\n\n```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2002,\n      \"finding\": \"Mammalian MafA was identified as the RIPE3b1 factor that binds the insulin gene enhancer element RIPE3b and activates insulin gene expression. Biochemical purification from beta-cell nuclear extracts identified RIPE3b1 as a mammalian homologue of avian MafA/L-Maf, with selective expression in pancreatic beta but not alpha cells.\",\n      \"method\": \"Biochemical purification, DNA-binding assays (EMSA), luciferase reporter assays, RT-PCR\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — biochemical purification plus functional binding and transactivation assays; replicated in same year by independent group (PMID:12368292)\",\n      \"pmids\": [\"12011435\", \"12368292\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"MafA protein and mRNA are up-regulated by glucose in beta cells, consistent with glucose-regulated binding of MafA to the RIPE3b element in beta-cell nuclear extracts. A dominant-negative form of MafA inhibited insulin promoter activity, demonstrating direct transcriptional activation.\",\n      \"method\": \"RT-PCR, EMSA, luciferase reporter assays with dominant-negative constructs\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (EMSA, reporter assay, dominant-negative), replicated across labs\",\n      \"pmids\": [\"12368292\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"MafA (quail) is phosphorylated at serines 14 and 65 within its transactivation domain by ERK2 in vitro. Mutation of these residues to alanine severely impairs transcriptional activity and abolishes MafA's ability to induce QR1 expression and neuroretina-to-lens transdifferentiation, establishing phosphorylation as essential for MafA biological activity.\",\n      \"method\": \"In vitro kinase assays with ERK2/p38/JNK/ERK5, site-directed mutagenesis (S14A, S65A), luciferase reporter assays, in ovo electroporation\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro kinase reconstitution plus mutagenesis plus functional readouts\",\n      \"pmids\": [\"11416124\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"MafA interacts directly with endogenous PDX-1 and BETA2 (NeuroD) in beta cells, forming a complex that synergistically activates the insulin gene promoter. Synergistic activation required intact MafA transactivation and DNA-binding domains. Dominant-negative and siRNA-mediated knockdown of MafA profoundly reduced insulin promoter activity in beta-cell lines.\",\n      \"method\": \"Co-immunoprecipitation (endogenous proteins), GST pull-down, luciferase reporter assays, dominant-negative constructs, siRNA knockdown, adenoviral overexpression in rat islets\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal Co-IP and GST pulldown plus functional epistasis via mutagenesis and siRNA, replicated across multiple assay systems\",\n      \"pmids\": [\"15665000\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"MafA is the only beta-cell-specific insulin gene activator and selectively induces endogenous insulin transcription in non-beta cells. MafA expression is first detected in insulin-producing cells during the second principal phase of beta-cell differentiation and is absent in Nkx6.1-null pancreata that lack second-phase beta cells, placing MafA downstream of Nkx6.1.\",\n      \"method\": \"Ectopic expression in non-beta cell lines, immunohistochemistry in Nkx6.1-/- pancreata, RT-PCR\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — ectopic expression and KO mouse epistasis; single lab\",\n      \"pmids\": [\"14973194\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"MafA-deficient mice develop glucose intolerance and diabetes mellitus. Glucose-, arginine-, and KCl-stimulated insulin secretion are severely impaired despite normal insulin content. Transcripts for insulin 1, insulin 2, Pdx1, Beta2, and Glut-2 are diminished in MafA-deficient islets, establishing MafA as a key in vivo regulator of glucose-stimulated insulin secretion.\",\n      \"method\": \"Targeted gene knockout in mice, glucose/arginine/KCl tolerance tests, RT-PCR, islet isolation and secretion assays\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo knockout with multiple physiological phenotypic readouts and target gene analysis\",\n      \"pmids\": [\"15923615\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"MafA overexpression together with PDX-1 and NeuroD markedly increases insulin gene expression and protein in liver, and dramatically ameliorates glucose tolerance in streptozotocin-induced diabetic mice, demonstrating that the combination of these three transcription factors is sufficient to reprogram non-beta cells toward insulin production.\",\n      \"method\": \"Adenoviral overexpression in vivo, glucose tolerance testing in diabetic mice, RT-PCR, Western blot\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vivo functional rescue experiment; single lab\",\n      \"pmids\": [\"15664997\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"FoxO1 forms a complex with PML and SIRT1 to activate MafA (and NeuroD) expression, protecting beta cells against oxidative stress. Acetylation-defective FoxO1 mutants fail to associate with PML, are subject to ubiquitin-dependent degradation, and cannot sustain MafA expression. Hyperglycemia suppresses MafA expression in vivo, and transgenic constitutively nuclear FoxO1 prevents this suppression.\",\n      \"method\": \"Co-immunoprecipitation (FoxO1-Pml-Sirt1 complex), acetylation-defective/mimicking mutants, transgenic mice with nuclear FoxO1, in vivo MafA expression analysis\",\n      \"journal\": \"Cell metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — Co-IP of complex, mutagenesis, and transgenic mouse epistasis; multiple orthogonal approaches\",\n      \"pmids\": [\"16154098\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"MafA phosphorylation by p38 MAP kinase occurs at threonine 113, threonine 57, and serine 272 (identified by mass spectrometry and Western blot). Mutation of these residues severely impairs MafA biological activity. p38 also phosphorylates MafB and c-Maf, implicating the p38 pathway as a novel regulator of large Maf transcription factors.\",\n      \"method\": \"Western blot, mass spectrometry, in vitro kinase assay with p38, site-directed mutagenesis\",\n      \"journal\": \"FEBS letters\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro kinase assay plus mass spectrometry identification of phosphosites plus mutagenesis\",\n      \"pmids\": [\"15963504\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Beta-cell-specific MafA transcription is controlled by region 3 (bp -8118 to -7750) of the mafA promoter. FoxA2, Nkx2.2, and PDX-1 were shown to specifically bind to region 3 in vivo (by ChIP) and activate MafA transcription through this region. siRNA knockdown of PDX-1 decreased mafA mRNA; MafA was absent in Nkx2.2-null pancreata.\",\n      \"method\": \"Chromatin immunoprecipitation (ChIP), luciferase reporter assays, siRNA knockdown, Nkx2.2 knockout mouse analysis, species conservation analysis\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — ChIP plus reporter mutagenesis plus in vivo KO epistasis; replicated across multiple approaches\",\n      \"pmids\": [\"16847327\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"MafA overproduction enhances binding to the insulin promoter and increases insulin mRNA and protein, while dominant-negative MafA diminishes both. MafA regulates expression of glucokinase, Glut2, PDX1, NKX6-1, GLP1R, PCSK1, and pyruvate carboxylase in INS-1 beta cells, establishing MafA as a master regulator of genes critical for metabolism-secretion coupling.\",\n      \"method\": \"Stable INS-1 cell lines with inducible MafA overexpression or dominant-negative MafA, EMSA, RT-PCR, insulin secretion assays\",\n      \"journal\": \"Diabetologia\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — inducible gain/loss-of-function with multiple molecular endpoints; thorough functional characterization\",\n      \"pmids\": [\"17149590\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"During embryonic pancreatic development, a switch from MafB to MafA expression accompanies beta-cell differentiation. Beta-cell differentiation proceeds through a MafB+/MafA-/Ins+ intermediate cell to a MafB-/MafA+/Ins+ mature state, and MafB-to-MafA transition follows induction of high PDX-1 expression. MafA, MafB, and cMaf can each activate insulin and glucagon reporter constructs, demonstrating functional redundancy, yet display distinct cell-type-specific expression.\",\n      \"method\": \"Immunohistochemistry, co-immunofluorescence, luciferase reporter assays with ectopic Maf factor expression\",\n      \"journal\": \"Developmental biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — developmental lineage mapping plus reporter assays; single lab\",\n      \"pmids\": [\"16580660\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Glucose induces MafA expression in beta-cell lines via the hexosamine biosynthetic pathway. Glucosamine stimulates MafA expression in the absence of high glucose; inhibition of hexosamine biosynthetic pathway abolishes glucose-induced MafA; and inhibition of O-GlcNAcase (which removes O-GlcNAc from proteins) stimulates MafA expression at low glucose, implicating O-linked glycosylation of an unknown protein as necessary for glucose-dependent MafA induction.\",\n      \"method\": \"Pharmacological inhibition of hexosamine pathway (azaserine), glucosamine supplementation, O-GlcNAcase inhibitors, RT-PCR, Western blot in INS-1 and MIN6 cells\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple pharmacological interventions converging on same pathway; single lab\",\n      \"pmids\": [\"17142462\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"MafA protein stability is regulated by glucose through glycogen synthase kinase 3 (GSK3)-mediated phosphorylation at multiple N-terminal sites in beta cells. Mutational analysis and pharmacological GSK3 inhibition demonstrated that constitutive GSK3 phosphorylation is a prerequisite for rapid MafA degradation under low-glucose conditions, and glucose stabilizes MafA by modulating this pathway.\",\n      \"method\": \"In vitro kinase assays, site-directed mutagenesis of phosphorylation sites, pharmacological GSK3 inhibition in MIN6 cells, cycloheximide chase experiments\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — mutagenesis plus pharmacological inhibition plus kinase assay; multiple orthogonal approaches\",\n      \"pmids\": [\"17682063\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"RIPE3b1/MafA binds directly to Area II of the pdx-1 gene 5'-flanking region (sequence blocks B4/5) with the same molecular mass and binding specificity as the insulin C1/RIPE3b1-binding protein. ChIP confirmed MafA binding to the Area II region of the endogenous pdx-1 gene, establishing that MafA directly regulates pdx-1 transcription.\",\n      \"method\": \"EMSA, molecular weight determination by gel fractionation, ChIP, Area II reporter assays with mutated binding sites\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — ChIP plus binding specificity assays plus reporter mutagenesis\",\n      \"pmids\": [\"12551916\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"MafA and MafB regulate Pdx1 transcription exclusively through Area II of the Pdx1 promoter in beta cells. In adult islets only MafA (not MafB) is bound to Area II by quantitative ChIP. In embryonic day 18.5 beta cells, both MafA and MafB are bound to Area II. A transgene driven by Pdx1 Areas I+II was severely compromised in MafB-/- mice, confirming MafB's requirement for Pdx1 expression during development.\",\n      \"method\": \"Quantitative ChIP, luciferase reporter assays, MafB knockout mouse analysis, transgenic reporter mice\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — quantitative ChIP plus genetic epistasis (KO mice) plus reporter assays\",\n      \"pmids\": [\"18522939\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Phosphorylation at Ser65 of mammalian MafA governs both protein stability and transactivation potential. Ser65 phosphorylation acts as the initial degradation signal, with ubiquitinylation occurring within the C-terminus (aa 234-359). Ser65Glu (phosphomimetic) produces an unstable but transactivation-potent protein; Ser65Ala blocks degradation but reduces transactivation. Ser14 phosphorylation enhances activation without affecting turnover.\",\n      \"method\": \"Site-directed mutagenesis (S65E, S65D, S65A, S14A), cycloheximide chase, ubiquitinylation assays, luciferase reporter assays, chimeric/deletion constructs\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — multiple phosphomimetic and phosphoablative mutations plus ubiquitinylation assay plus functional readouts in same study\",\n      \"pmids\": [\"19004825\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"MafA is post-translationally modified by SUMO-1 and SUMO-2 at Lys32. SUMOylation increases under low glucose or hydrogen peroxide conditions. A SUMOylation-deficient mutant (K32R) shows increased transcriptional activity toward the insulin gene promoter and increased suppression of the CHOP-10 promoter. SUMOylation does not affect nuclear localization or ubiquitin-dependent degradation of MafA.\",\n      \"method\": \"SUMO modification assays, site-directed mutagenesis (K32R), luciferase reporter assays, beta-cell treatment with low glucose and H2O2, nuclear localization assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — site-specific mutagenesis plus functional transactivation assays plus conditions-dependent SUMO modification\",\n      \"pmids\": [\"19029092\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"p38 MAPK is a major regulator of MafA protein stability specifically under oxidative stress. p38 MAPK inhibition enhances MafA stability under both low and high glucose; simultaneous mutation of Thr57 and Thr134 to alanine prevents p38-mediated degradation. Under oxidative stress, reduced GSK3-pathway activity (via decreased PA28γ) makes p38 MAPK the dominant degradation pathway.\",\n      \"method\": \"Pharmacological p38 inhibition (SB203580), site-directed mutagenesis (T57A, T134A double mutant), cycloheximide chase in MIN6 and mouse islets, oxidative stress experiments\",\n      \"journal\": \"Molecular endocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — pharmacological inhibition plus mutagenesis plus islet validation; multiple conditions tested\",\n      \"pmids\": [\"19407223\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"MafA expression in Pdx1+ pancreatic progenitors is detrimental to pancreatic development. Transgenic MafA expression in Pdx1+ cells reduces pancreatic mass and progenitor proliferation, at least partially through induction of cyclin kinase inhibitors p27 and p57, and disproportionately inhibits endocrine cell formation.\",\n      \"method\": \"Transgenic mouse model (MafA in Pdx1+ cells), immunohistochemistry, BrdU proliferation assay, cyclin inhibitor analysis (p27, p57)\",\n      \"journal\": \"Developmental biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — transgenic gain-of-function with mechanistic target identification; single lab\",\n      \"pmids\": [\"19576197\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Specific subtypes of low-threshold mechanoreceptors (LTMs) in dorsal root ganglia selectively express MafA. In Ret-deficient mice, MafA expression is reduced and central/peripheral LTM projections are compromised. In MafA mutant mice, a discrete subset of LTMs displays altered neurotrophic factor receptor expression, establishing a genetic interaction between Ret signaling and MafA in LTM specification.\",\n      \"method\": \"Immunohistochemistry, in situ hybridization, Ret knockout mouse analysis, MafA mutant mouse analysis, axon projection tracing\",\n      \"journal\": \"Neuron\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — two independent knockout models with distinct phenotypic readouts establishing genetic epistasis\",\n      \"pmids\": [\"20064392\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Phosphorylation within the MafA N-terminal transactivation domain (aa 1-72) is required for C-terminal dimerization and DNA binding. Dephosphorylation abolishes detection of MafA dimers and dramatically reduces DNA-binding ability. Analysis of MafA/MafB chimeras showed that the C-terminal dimerization region of MafA (aa 279-359) confers phosphorylation-sensitive DNA binding, whereas the homologous MafB region conveys phosphorylation-independent binding.\",\n      \"method\": \"Mass spectrometry (phosphosite identification), dephosphorylation assays, MafA/MafB chimeric protein analysis, EMSA, mutagenesis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — mass spectrometry plus biochemical dephosphorylation plus chimeric protein domain mapping\",\n      \"pmids\": [\"20208071\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"MafA regulates postnatal beta-cell function by controlling expression of genes for glucose sensing, hormone processing, vesicle formation, and insulin secretion. Microarray profiling of MafB-/- embryonic pancreata and adult MafA-null islets showed overlapping target genes, demonstrating sequential regulation: MafB controls these genes developmentally and MafA sustains their expression in adults.\",\n      \"method\": \"Microarray profiling of MafB-/- (E18.5) and pancreas-specific MafA-null adult islets, quantitative RT-PCR, in situ hybridization, immunohistochemistry\",\n      \"journal\": \"Diabetes\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genome-wide transcriptomic analysis in two distinct KO models with validation\",\n      \"pmids\": [\"20627934\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Mafa overexpression in neonatal rat islets (via adenovirus) induces acquisition of glucose-responsive insulin secretion, increasing both the percentage of secreting beta cells and insulin secreted per cell, approaching adult levels. Mafa specifically upregulates Neurod1, Nkx6-1, glucokinase, and Glp1r mRNAs, identifying a gene expression program downstream of Mafa that drives functional maturation.\",\n      \"method\": \"Adenoviral Mafa overexpression in P2 rat islets, static insulin secretion assays, reverse haemolytic plaque assay (RHPA), quantitative RT-PCR\",\n      \"journal\": \"Diabetologia\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — adenoviral gain-of-function with functional secretion readout and target gene identification; replicated across assay systems\",\n      \"pmids\": [\"21190012\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"c-Jun, upregulated by reactive oxygen species under diabetic conditions, suppresses MafA expression. Adenoviral overexpression of c-Jun in MIN6 cells and isolated islets significantly decreased MafA protein and mRNA, with concomitant suppression of insulin expression. MafA overexpression restored insulin promoter activity suppressed by c-Jun, placing c-Jun upstream of MafA in a ROS-mediated pathway.\",\n      \"method\": \"Adenoviral c-Jun overexpression in MIN6 and primary islets, Western blot, immunohistochemistry in db/db mice, insulin promoter luciferase reporter\",\n      \"journal\": \"Diabetes\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — gain-of-function plus epistasis rescue experiment; single lab\",\n      \"pmids\": [\"20424231\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"ATF2 is a component of the RIPE3b1 activator complex. ATF2 alone cannot bind the C1/RIPE3b element but acquires binding capacity through complex formation with MafA. ATF2 also interacts with PDX-1 and BETA2. Co-expression of ATF2 with MafA, PDX-1, and BETA2 results in synergistic insulin promoter activation. RNAi knockdown of ATF2 in MIN6 cells reduces endogenous insulin mRNA.\",\n      \"method\": \"Co-immunoprecipitation (ATF2-MafA interaction), EMSA with ATF2/MafA complex, luciferase reporter assays, RNAi knockdown, immunohistochemistry of mouse pancreas\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — Co-IP plus EMSA plus RNAi knockdown with functional readout\",\n      \"pmids\": [\"21278380\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Proteasome activator PA28γ (REGγ/PSME3) stimulates GSK3-phosphorylated MafA degradation via the 20S proteasome. PA28γ binds to phosphorylated MafA; alanine substitutions at GSK3 phosphorylation sites (Ser49, Thr53, Thr57, Ser61, Ser65) prevent PA28γ binding and confer resistance to degradation. PA28γ-mediated MafA degradation occurs through a distinct mechanism from its degradation of p21.\",\n      \"method\": \"Co-immunoprecipitation (PA28γ-MafA), site-directed mutagenesis (phosphorylation site alanine substitutions), proteasome activity assays, luciferase reporter assays, PA28γ mutant analysis (N151Y, K188D)\",\n      \"journal\": \"Journal of molecular endocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — Co-IP plus mutagenesis plus mechanistic differentiation from known PA28γ substrate; multiple orthogonal approaches\",\n      \"pmids\": [\"21646385\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"SUMOylation of MafA at Lys32 negatively regulates its transcriptional and oncogenic activities. A K32R SUMOylation-deficient mutant more potently transactivates crystallin and insulin gene promoters, more efficiently induces ectopic crystallin expression in developing chick embryo, and has enhanced ability to induce colony formation in DF-1 fibroblasts, demonstrating that SUMO modification restrains both transcriptional and transforming activities.\",\n      \"method\": \"Site-directed mutagenesis (K32R), luciferase reporter assays, in ovo electroporation, colony formation assay in DF-1 cells\",\n      \"journal\": \"Genes to cells\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — site-specific mutation with multiple functional readouts across cell types\",\n      \"pmids\": [\"20718938\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"miR-30d induces MafA expression by directly targeting MAP4K4 (a TNF-α-activated kinase), thereby de-repressing MafA. Overexpression of miR-30d prevents TNF-α-induced reduction in both MafA and IRS2. Overexpression of MAP4K4 suppresses MafA, and miR-30d overexpression protects against MAP4K4-mediated suppression of insulin transcription and secretion.\",\n      \"method\": \"miR-30d overexpression in beta cells, luciferase 3'UTR reporter assay (MAP4K4 as direct target), Western blot, RT-PCR, insulin secretion assays, db/db mouse islet analysis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — 3'UTR reporter validation plus gain-of-function experiments; single lab\",\n      \"pmids\": [\"22733810\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Thyroid hormone (triiodothyronine/T3) directly binds to the Mafa promoter region via thyroid hormone receptor, activating Mafa transcription. In vitro exposure of immature rat islets to T3 enhanced Mafa expression and glucose-responsive insulin secretion, effects abolished by dominant-negative Mafa. In vivo, neonatal T3 supplementation accelerated metabolic development; T3 inhibition delayed it.\",\n      \"method\": \"ChIP (thyroid hormone receptor binding to Mafa promoter), EMSA, luciferase reporter assay, dominant-negative Mafa in vitro, neonatal rat T3 manipulation in vivo\",\n      \"journal\": \"Diabetes\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — direct receptor-ligand ChIP plus EMSA plus functional reporter plus dominant-negative epistasis plus in vivo intervention\",\n      \"pmids\": [\"23305647\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"p38 MAPK directly binds MafA and triggers its degradation via the ubiquitin-proteasomal pathway. Under oxidative stress (but not non-oxidative conditions), MafA degradation depends on p38-mediated phosphorylation at Thr134 (not Thr57). Expression of T134A-MafA (but not T57A-MafA) reduced oxidative stress-mediated loss of glucose-stimulated insulin secretion, independent of p38 action on protein kinase D.\",\n      \"method\": \"Co-immunoprecipitation (p38-MafA direct binding), site-directed mutagenesis (T134A, T57A), proteasome inhibitor experiments, insulin secretion assays under oxidative stress\",\n      \"journal\": \"Molecular endocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct binding by Co-IP plus site-specific mutagenesis plus functional insulin secretion readout\",\n      \"pmids\": [\"23660596\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"MafA is required for postnatal beta-cell proliferation via the prolactin signaling pathway. MafA directly transactivates the prolactin receptor (Prlr) promoter, and loss of MafA reduces Prlr and Cyclin D2 (Ccnd2) expression. Prolactin stimulation of beta cells triggers phosphorylation and translocation of Stat5B and increases nuclear Cyclin D2 pool via Prlr/Jak2 signaling, resulting in proliferation. MafA-null mice show impaired beta-cell proliferation at 4 weeks.\",\n      \"method\": \"Transcriptome analysis (MafA KO islets), Prlr promoter luciferase reporter and ChIP, prolactin stimulation of beta cells, Stat5B phosphorylation assays, BrdU proliferation in MafA-null mice\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — ChIP plus promoter reporter plus pathway stimulation plus in vivo KO phenotype\",\n      \"pmids\": [\"25126749\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Loss of MafA reduces the beta-to-alpha cell ratio without hyperglycemia, and lineage tracing shows that most MafA-null former beta cells lose insulin expression while a minority convert to glucagon-expressing cells. MafA-null islets upregulate genes normally repressed in mature beta cells and transiently express endocrine progenitor transcription factors, hallmarks of dedifferentiation. This dedifferentiation also occurs in db/db and STZ diabetic models alongside MafB re-expression.\",\n      \"method\": \"MafA knockout mice, lineage tracing (Cre-lox), immunohistochemistry, gene expression analysis of dedifferentiation markers\",\n      \"journal\": \"Diabetologia\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic lineage tracing plus KO phenotyping with molecular characterization of cell fate\",\n      \"pmids\": [\"25500951\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"MafA becomes functionally essential to beta cells soon after birth. Islet organization, beta-cell mass, and function are compromised by 3 weeks in Mafa-null mice and earlier in Mafa/Mafb compound mutants. Genome-wide microarray identified MafA targets including cyclin D2 (controlling beta-cell replication) and genes affecting granule docking (affecting first-phase insulin secretion), substantiated by electron microscopy.\",\n      \"method\": \"Conditional Mafa knockout mice (MafaΔpanc), compound Mafa/Mafb mutants, genome-wide microarray, electron microscopy of granule docking, metabolic assays\",\n      \"journal\": \"Diabetes\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple KO models + genome-wide profiling + ultrastructural EM + metabolic functional assays\",\n      \"pmids\": [\"24520122\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"MLL3 and MLL4 histone H3K4 methyltransferase complexes bind to both MafA and MAFB transcription factors in beta cells. Unbiased in-cell biochemical and mass spectrometry identified all subunits of MLL3/4 complexes as MafA-interacting proteins. MafA is associated with the ~1.5 MDa MLL3/4 complexes in size-fractionated beta-cell extracts. Knockdown of NCOA6 (core MLL3/4 subunit) reduces expression of MafA/MafB target genes.\",\n      \"method\": \"In-cell biochemistry plus mass spectrometry (unbiased pulldown), size-fractionation/Co-IP, NCOA6 siRNA knockdown, NCoA6 conditional knockout in beta cells\",\n      \"journal\": \"Diabetes\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — unbiased mass spectrometry identification plus Co-IP in native complex plus genetic validation (KO mice)\",\n      \"pmids\": [\"26180087\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"HMGA1 physically interacts with PDX-1 and MafA (both in vitro by GST pulldown and in vivo by Co-IP). HMGA1 overexpression enhances the transactivating activity of PDX-1 and MafA on human and mouse insulin promoters; HMGA1 knockdown reduces this activity. High glucose stimulus increases HMGA1 binding to the insulin gene promoter (ChIP), indicating HMGA1 acts as a glucose-sensitive co-activator.\",\n      \"method\": \"GST pull-down, Co-immunoprecipitation, ChIP, luciferase reporter assays, siRNA knockdown, glucose stimulation\",\n      \"journal\": \"Frontiers in endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — Co-IP plus GST pulldown plus ChIP plus functional reporter; single lab\",\n      \"pmids\": [\"25628604\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"MAFA directly controls ANS-mediated insulin secretion by activating transcription of nicotinic receptor genes ChrnB2 and ChrnB4, and adrenergic receptor gene Adra2A. Acetylcholine-mediated insulin secretion requires nicotinic signaling, and nicotinic receptor expression is positively correlated with insulin secretion. MAFA binding to the ChrnB4 regulatory region was demonstrated by ChIP.\",\n      \"method\": \"MafA-deficient mouse model, ChIP (MafA binding to nicotinic receptor gene loci), pharmacological nicotinic receptor blockade, insulin secretion assays, correlation with human islet data\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — ChIP plus KO mouse plus pharmacological epistasis plus functional secretion assays\",\n      \"pmids\": [\"26904947\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Mafa potentiates PDX-1's ability to induce beta-cell formation from Ngn3-positive endocrine precursors and enables PDX-1 to produce beta cells from glucagon-positive alpha cells in vivo. Transgenic conditional expression of Mafa and/or Pdx1 in Ngn3+ progenitors and glucagon+ alpha cells demonstrated that Mafa is required to permit Pdx1-driven alpha-to-beta transdifferentiation.\",\n      \"method\": \"Conditional transgenic mouse models (Mafa and/or Pdx1 in Ngn3-Cre or glucagon-Cre lineages), lineage tracing, immunohistochemistry, hormone expression analysis\",\n      \"journal\": \"Diabetes\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo genetic epistasis using multiple conditional transgenic models\",\n      \"pmids\": [\"28223284\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"A missense MAFA mutation (p.Ser64Phe) causes familial insulinomatosis and diabetes by impairing phosphorylation within the transactivation domain, profoundly increasing MAFA protein stability under both high and low glucose conditions. The p.Ser64Phe mutation also enhances the transactivation potential of MAFA in beta-cell lines.\",\n      \"method\": \"Exome sequencing, functional studies of p.Ser64Phe in beta-cell lines (protein stability assays with cycloheximide chase, luciferase reporter for transactivation), phosphorylation analysis\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — disease-associated variant with mechanistic characterization (stability + transactivation assays) replicated in two independent families\",\n      \"pmids\": [\"29339498\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Long noncoding RNA Meg3 epigenetically regulates MafA expression in beta cells via EZH2-mediated H3K27 trimethylation of Rad21, Smc3, and Sin3α promoters. Knockdown of Meg3 or Ezh2 upregulates Rad21, Smc3, and Sin3α, which directly repress the MafA promoter. Inhibition of Rad21, Smc3, or Sin3α individually leads to upregulated MafA expression and increased insulin production.\",\n      \"method\": \"ChIP-qPCR (EZH2/H3K27me3 at Rad21/Smc3/Sin3α promoters), RNA immunoprecipitation-qPCR (Meg3-EZH2 binding), RNAi knockdown of Meg3/Ezh2/Rad21/Smc3/Sin3α, Western blot, RT-PCR in MIN6 and mouse islets\",\n      \"journal\": \"Cellular physiology and biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP plus RIP plus multiple RNAi validations; single lab\",\n      \"pmids\": [\"29529600\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"MafA directly regulates the voltage-gated Ca2+ channel subunit CaVγ4 (Cacng4) in beta cells. ChIP confirmed MafA binding to the CaVγ4 gene. CaVγ4 reduction in MafA-knockout mice suppresses L-type CaV1.2 and CaV1.3 expression, thereby suppressing voltage-gated Ca2+ entry and glucose-stimulated insulin exocytosis.\",\n      \"method\": \"ChIP (MafA binding to CaVγ4 gene), beta-cell-specific MafA knockout mice, patch-clamp electrophysiology (Ca2+ channel recordings), insulin exocytosis assays\",\n      \"journal\": \"Communications biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — ChIP plus genetic KO plus electrophysiology plus functional exocytosis assay\",\n      \"pmids\": [\"30911681\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Kindlin-2, through its C-terminal region, directly binds to and stabilizes MafA protein in beta cells. Kindlin-2 deletion causes severe diabetes-like phenotypes; reduced MafA activity impairs insulin expression. Kindlin-2 loss also activates GSK-3β and downregulates β-catenin, reducing beta-cell proliferation and mass.\",\n      \"method\": \"Co-immunoprecipitation (Kindlin-2–MafA interaction, C-terminal domain mapping), Kindlin-2 conditional knockout mice, insulin secretion from primary human and mouse islets, Ca2+ release assays, GSK-3β/β-catenin pathway analysis\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — Co-IP with domain mapping plus conditional KO with mechanistic pathway analysis\",\n      \"pmids\": [\"31980627\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"The MAFA S64F mutation causes sex-biased beta-cell dysfunction by inducing premature aging and cellular senescence selectively in males. Male MafaS64F/+ mice display transiently higher MafA protein levels preceding glucose intolerance. MAFAS64F production in male human beta cells accelerates cellular senescence and increases senescence-associated secretory proteins compared to cells expressing MAFAWT.\",\n      \"method\": \"S64F knock-in mouse model, glucose tolerance testing, sex-stratified analysis, gene expression profiling (Ca2+ signaling, DNA damage, aging/senescence pathways), cellular senescence assays in human beta cells\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — knock-in mouse model plus human cell validation with multiple molecular senescence readouts\",\n      \"pmids\": [\"34644565\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"METTL3-mediated m6A methylation regulates MafA mRNA stability in beta cells. Silencing METTL3 reduces m6A levels, MafA mRNA stability, and MafA protein expression, impairing glucose-stimulated insulin secretion. Overexpression of MafA rescues the decrease in GSIS caused by METTL3 silencing, while MafA silencing blocks METTL3 overexpression-mediated rescue, placing MafA downstream of METTL3/m6A modification.\",\n      \"method\": \"m6A-seq/quantification, METTL3 siRNA knockdown and overexpression, mRNA stability assays, luciferase reporter (MafA mRNA), MafA overexpression rescue, insulin secretion assays\",\n      \"journal\": \"Frontiers in endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — m6A quantification plus stability assay plus bidirectional epistasis rescue experiment; single lab\",\n      \"pmids\": [\"35872977\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"Avian mafA encodes a novel large Maf protein expressed in the differentiating neuroretina. MafA binds to MARE sequences and heterodimerizes with v-Maf, MafB, Jun, and Fos (but not small Maf proteins MafF/MafK). Increased MafA expression induces sustained proliferation of postmitotic quail neuroretinal cells.\",\n      \"method\": \"cDNA cloning, EMSA (MARE binding), co-immunoprecipitation/heterodimerization assays, ectopic expression in quail neuroretinal cells\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — initial characterization of dimerization partners plus functional proliferation assay; foundational paper\",\n      \"pmids\": [\"9674710\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"MafA's strong cell-transforming ability maps to its DNA-binding domain. Chimeras of MafA and MafB correlate the strong transformation capacity of MafA with its DNA-binding domain, while weak transactivation also maps to this domain. Cell transformation and transactivation by MafA are controlled by phosphorylation of two conserved serine residues in the transactivation domain.\",\n      \"method\": \"MafA/MafB chimeric protein analysis, chicken embryo fibroblast transformation assay, luciferase reporter assays, site-directed mutagenesis of serine residues\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — chimeric domain mapping plus functional transformation assay plus mutagenesis; single lab\",\n      \"pmids\": [\"12970735\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"MafA directly binds to and activates MaoA and MaoB (monoamine oxidase) transcriptional control sequences in pancreatic beta cells (demonstrated by ChIP). MaoA and MaoB are expressed in mouse islet beta cells; inhibition of Mao activity reduces insulin secretion. MaoB expression is reduced in MafA-deficient mice and in type 2 diabetic mouse and human islets.\",\n      \"method\": \"ChIP (MafA binding to MaoA/MaoB gene regulatory regions), MafA-deficient mouse analysis, pharmacological Mao inhibition, insulin secretion assays\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — ChIP plus KO mouse plus pharmacological inhibition; single lab\",\n      \"pmids\": [\"26546820\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"PPP1R1A (protein phosphatase 1 inhibitor protein 1A) is a MafA target gene required for GLP1R-mediated amplification of glucose-stimulated insulin secretion. MafA loss or acute knockdown reduces PPP1R1A expression. PPP1R1A silencing impairs GSIS amplification, PKA-target phosphorylation, mitochondrial coupling efficiency, and expression of critical beta-cell genes including MafA, Pdx1, NeuroD1, and Pax6.\",\n      \"method\": \"MafA-deficient mouse islet transcriptomics, siRNA knockdown of PPP1R1A in INS1 cells, insulin secretion assays (GLP1-amplified GSIS), PKA substrate phosphorylation assays, mitochondrial coupling efficiency measurements\",\n      \"journal\": \"Metabolism: clinical and experimental\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — KO transcriptomics plus RNAi with functional secretion and pathway assays; single lab\",\n      \"pmids\": [\"33631146\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"MAFA is a beta-cell-enriched basic leucine zipper (bZIP) transcription factor that binds the insulin gene C1/RIPE3b element and synergistically activates insulin transcription with PDX-1 and BETA2/NeuroD via a direct physical complex; its activity, stability, and DNA-binding capacity are tightly regulated by phosphorylation (by GSK3, ERK2, p38 MAPK) at multiple N-terminal serines/threonines—which govern ubiquitin-proteasome-mediated degradation facilitated by PA28γ—as well as by SUMOylation at Lys32 (which represses transactivation) and glucose-driven stabilization via the hexosamine/O-GlcNAc pathway; upstream, FoxO1/PML/SIRT1, thyroid hormone receptor, and FoxA2/Nkx2.2/PDX-1 control MAFA transcription through the conserved region 3 of its promoter, while c-Jun and p38 MAPK suppress it under diabetic/oxidative-stress conditions; MafA directly regulates a broad beta-cell gene program including Pdx1, Glut2, glucokinase, GLP1R, nicotinic receptors (ChrnB2/B4), Ca2+ channel subunit CaVγ4, monoamine oxidases, PPP1R1A, and prolactin receptor (driving postnatal beta-cell proliferation via Jak2/Stat5B/Cyclin D2); in vivo, MafA is dispensable for initial beta-cell specification but essential for postnatal functional maturation, maintenance of beta-cell identity (loss causes dedifferentiation and alpha-cell conversion), and neurosensory low-threshold mechanoreceptor specification via a Ret-MafA genetic interaction; disease-associated gain-of-stability mutations (S64F) increase protein levels and enhance transactivation, causing insulinomatosis or diabetes through premature senescence in a sex-biased manner.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"MAFA is a beta-cell-enriched basic leucine zipper (bZIP) transcription factor that serves as a master regulator of insulin gene transcription, glucose-stimulated insulin secretion, and beta-cell identity. It binds the RIPE3b/C1 element of the insulin promoter and synergistically activates transcription through direct physical interactions with PDX-1 and BETA2/NeuroD, recruiting MLL3/MLL4 histone methyltransferase complexes to drive expression of a broad beta-cell gene program including Glut2, GLP1R, Pcsk1, nicotinic receptors, CaVγ4, prolactin receptor, and PPP1R1A [PMID:12011435, PMID:15665000, PMID:26180087, PMID:17149590, PMID:26904947, PMID:30911681]. MafA protein levels are tightly controlled by glucose-responsive post-translational modifications: GSK3 phosphorylation primes PA28γ-mediated proteasomal degradation under low glucose, p38 MAPK phosphorylation drives degradation under oxidative stress, ERK2 phosphorylation at Ser14 enhances transactivation, and SUMOylation at Lys32 attenuates transcriptional activity; critically, N-terminal phosphorylation is required for dimerization and DNA binding [PMID:17682063, PMID:19407223, PMID:19004825, PMID:19029092, PMID:20208071, PMID:21646385]. Loss of MafA causes beta-cell dedifferentiation and diabetes in mice, while the human gain-of-stability mutation MAFA p.Ser64Phe, which blocks phosphodegron-dependent turnover, causes familial insulinomatosis or sex-biased diabetes through accelerated beta-cell senescence [PMID:15923615, PMID:25500951, PMID:29339498, PMID:34644565].\",\n  \"teleology\": [\n    {\n      \"year\": 2001,\n      \"claim\": \"Establishing that MafA is a phosphoprotein whose transcriptional and biological activity depends on ERK2-mediated phosphorylation at Ser14 and Ser65 resolved how MAPK signaling modulates large Maf factor function.\",\n      \"evidence\": \"In vitro kinase assays with ERK2, p38, JNK, ERK5; site-directed mutagenesis; reporter and in ovo transdifferentiation assays\",\n      \"pmids\": [\"11416124\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological relevance in beta cells not yet tested\", \"Whether phosphorylation controls stability versus activity was unresolved\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Identification of MafA as the long-sought RIPE3b1 transcription factor that binds the insulin enhancer and is selectively expressed in beta cells established the molecular identity of a key insulin gene activator and its glucose responsiveness.\",\n      \"evidence\": \"Biochemical purification of RIPE3b1 activity, cloning of human MAFA, EMSA, reporter assays, RT-PCR showing glucose regulation\",\n      \"pmids\": [\"12011435\", \"12368292\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo requirement for insulin expression not yet demonstrated\", \"Mechanism of glucose-dependent regulation unknown\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Demonstrating that MafA directly binds and activates the Pdx1 promoter (Area II) revealed a positive regulatory loop between two master beta-cell transcription factors, and chimeric analysis mapped transforming activity to the MafA DNA-binding domain.\",\n      \"evidence\": \"ChIP, EMSA, reporter assays for Pdx1 regulation; chicken embryo fibroblast transformation assay with MafA/MafB chimeras\",\n      \"pmids\": [\"12551916\", \"12970735\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether MafA-Pdx1 loop operates in vivo during development was untested\", \"Oncogenic relevance in mammalian cells not established\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"MafA knockout mice developing glucose intolerance and diabetes with impaired insulin secretion and reduced expression of key beta-cell genes (insulin, Pdx1, Beta2, Glut2) proved MafA is essential for beta-cell function in vivo; concurrently, physical interaction with PDX-1 and BETA2 was shown to underlie synergistic insulin promoter activation, and p38 MAPK phosphorylation sites were mapped.\",\n      \"evidence\": \"MafA KO mice with metabolic phenotyping; Co-IP/GST pull-down for PDX-1/BETA2 interactions; mass spectrometry and mutagenesis for p38 sites\",\n      \"pmids\": [\"15923615\", \"15665000\", \"15963504\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of beta-cell failure (dedifferentiation vs. death) unresolved\", \"Redundancy with MafB in adult beta cells not addressed\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Discovery that FoxO1 forms a complex with Pml and Sirt1 to activate MafA expression under oxidative stress provided the first upstream transcriptional pathway linking metabolic stress to MafA regulation.\",\n      \"evidence\": \"Co-IP of FoxO1–Pml–Sirt1 complex, transgenic mouse rescue of hyperglycemia-induced MafA loss\",\n      \"pmids\": [\"16154098\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether FoxO1 acts directly on the MafA promoter was not shown\", \"How hyperglycemia suppresses MafA independent of oxidative stress was unknown\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Mapping the conserved region 3 (R3) of the MafA promoter as the principal beta-cell-specific regulatory element, bound by FoxA2, Nkx2.2, and PDX-1, and showing glucose induces MafA via the hexosamine biosynthetic pathway/OGT defined both the cis-regulatory architecture and metabolic sensing mechanism for MafA transcription.\",\n      \"evidence\": \"ChIP, mutational reporter analysis, siRNA, Nkx2.2-null mice for promoter; pharmacological inhibitors and OGT manipulation for hexosamine pathway\",\n      \"pmids\": [\"16847327\", \"17142462\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether O-GlcNAcylation acts directly on MafA promoter-bound factors was unknown\", \"Epigenetic regulation of R3 not explored\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Establishing that GSK3 constitutively phosphorylates MafA at N-terminal sites to promote rapid proteasomal degradation under low glucose explained how glucose post-translationally stabilizes MafA protein, complementing the transcriptional glucose response.\",\n      \"evidence\": \"GSK3 pharmacological inhibition in MIN6 cells, phosphorylation site mutagenesis, pulse-chase stability assays\",\n      \"pmids\": [\"17682063\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the E3 ubiquitin ligase unknown\", \"How glucose inhibits GSK3 phosphorylation of MafA specifically was unclear\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Dissecting the distinct roles of Ser65 phosphorylation (degradation signal with C-terminal ubiquitinylation) versus Ser14 phosphorylation (transactivation enhancement), and discovering that SUMOylation at Lys32 attenuates transcriptional activity without affecting stability, delineated a phosphorylation-SUMOylation code governing MafA output.\",\n      \"evidence\": \"Phosphomimetic/phosphoablative mutagenesis, ubiquitination assays, in-cell SUMOylation assays, K32R mutant analysis\",\n      \"pmids\": [\"19004825\", \"19029092\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"SUMO E3 ligase identity unknown\", \"Interplay between SUMOylation and phosphorylation not resolved\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Showing that p38 MAPK specifically mediates oxidative-stress-dependent MafA degradation (distinct from GSK3-mediated low-glucose degradation) identified parallel degradation pathways responding to different pathological signals; separately, MafA expression in pancreatic progenitors was shown to induce cell-cycle exit via p27/p57.\",\n      \"evidence\": \"Pharmacological epistasis with p38/GSK3 inhibitors in MIN6 and islets; Thr57/Thr134 mutagenesis; conditional MafA transgene in Pdx1+ progenitors\",\n      \"pmids\": [\"19407223\", \"19576197\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether p38 and GSK3 pathways converge on the same ubiquitin ligase was unknown\", \"Relevance of progenitor cell-cycle arrest to normal development unclear\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Demonstrating that N-terminal phosphorylation is required for MafA dimerization and DNA binding (unlike MafB) revealed a unique allosteric mechanism coupling signaling to DNA-binding competence; concurrently, Nkx6.1 and Pax6 were identified as direct activators of MafA through R3, establishing MafA autoregulation.\",\n      \"evidence\": \"Mass spectrometry, dephosphorylation/chimera analysis, EMSA; transgenic reporter mice with R3 deletion, ChIP, Nkx6.1/Pax6 KO mice\",\n      \"pmids\": [\"20208071\", \"20584984\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of phosphorylation-dependent dimerization unknown\", \"Whether MafA directly binds its own R3 element was not definitively shown\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Identifying PA28γ as the adaptor linking GSK3-phosphorylated MafA to proteasomal degradation completed the phosphodegron-to-proteasome pathway, and discovery of ATF2 as a MafA-dependent co-factor that acquires RIPE3b-binding capacity only upon complexing with MafA expanded the insulin promoter activation model.\",\n      \"evidence\": \"Co-IP of PA28γ with phospho-MafA, mutagenesis, proteasome inhibition; Co-IP/EMSA of ATF2–MafA complex, siRNA knockdown\",\n      \"pmids\": [\"21646385\", \"21278380\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether PA28γ is the sole proteasomal targeting pathway was unknown\", \"ATF2–MafA stoichiometry and in vivo relevance not established\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Thyroid hormone receptor directly binding the MafA promoter and T3 inducing MafA-dependent functional maturation of beta cells established an endocrine axis controlling postnatal acquisition of glucose-responsive insulin secretion.\",\n      \"evidence\": \"ChIP, EMSA, reporter assays, dominant-negative MafA, neonatal T3 supplementation/inhibition in vivo\",\n      \"pmids\": [\"23305647\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether T3–MafA axis operates in human beta-cell maturation was untested\", \"Interaction with other maturation signals (e.g., weaning) not addressed\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Lineage tracing in MafA KO mice revealed that loss of MafA causes beta-cell dedifferentiation (not death), with re-expression of progenitor markers and partial conversion to glucagon+ cells, redefining the pathological consequence of MafA loss; MafA was also shown to drive postnatal beta-cell proliferation via the prolactin receptor/Jak2/Stat5B/cyclin D2 axis.\",\n      \"evidence\": \"Lineage tracing and immunofluorescence in MafA KO mice; Prlr promoter reporter, prolactin stimulation, Stat5B phosphorylation in KO mice\",\n      \"pmids\": [\"25500951\", \"25126749\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether dedifferentiated cells can be redifferentiated by MafA restoration was unknown\", \"Whether Prlr pathway operates in human beta cells not tested\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Discovery that MafA physically associates with MLL3/MLL4 histone methyltransferase complexes provided a chromatin-level mechanism for MafA-driven gene activation; in parallel, MafA target genes were expanded to include nicotinic receptors controlling autonomic insulin secretion and monoamine oxidases.\",\n      \"evidence\": \"Mass spectrometry interactome, Co-IP, NCOA6 conditional KO; ChIP on ChrnB2/B4/MaoA/MaoB promoters, nicotinic agonist secretion assays in MafA KO mice\",\n      \"pmids\": [\"26180087\", \"26904947\", \"26546820\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether MLL3/4 recruitment is direct or via intermediary subunits was unresolved\", \"Functional significance of MaoA/B in beta cells beyond expression correlation not shown\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Identification of the human MAFA p.Ser64Phe mutation causing familial insulinomatosis/diabetes by blocking phosphodegron-dependent turnover translated the phosphorylation-stability mechanism into human disease, and lncRNA Meg3 was shown to epigenetically regulate MafA via EZH2-mediated repression of cohesin/Sin3α.\",\n      \"evidence\": \"Exome sequencing in two families, protein stability and transactivation assays in beta cell lines; ChIP-qPCR, RNA immunoprecipitation, Meg3/EZH2 siRNA in MIN6/islets\",\n      \"pmids\": [\"29339498\", \"29529600\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism by which S64F leads to insulinoma versus diabetes in different individuals unclear\", \"Meg3–MafA axis not validated in human islets\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"MafA was shown to transcriptionally control CaVγ4 (CACNG4), directly linking MafA to L-type Ca²⁺ channel regulation and voltage-gated calcium entry required for insulin exocytosis.\",\n      \"evidence\": \"ChIP, beta-cell-specific MafA KO mice, Ca²⁺ imaging, insulin secretion assays\",\n      \"pmids\": [\"30911681\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether CaVγ4 loss fully accounts for the secretion defect in MafA KO was untested\", \"Other ion channel targets of MafA not systematically surveyed\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Kindlin-2 was identified as a protein stabilizer of MafA through direct C-terminal binding, providing an integrin-linked mechanism for maintaining MafA levels and beta-cell mass.\",\n      \"evidence\": \"Co-IP domain mapping, conditional Kindlin-2 KO in mice, Ca²⁺ imaging, beta-cell proliferation assays\",\n      \"pmids\": [\"31980627\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of Kindlin-2–MafA interaction unknown\", \"Whether Kindlin-2 competes with PA28γ for MafA binding not tested\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"The MAFA S64F knock-in mouse revealed sex-biased beta-cell senescence as the pathogenic mechanism: transiently elevated MafA protein in males preceded glucose intolerance, accelerated DNA damage, and senescence-associated secretory phenotype, explaining the sex-dependent penetrance of MAFA-linked diabetes.\",\n      \"evidence\": \"S64F knock-in mice, glucose tolerance tests, transcriptomics, human beta cell senescence assays\",\n      \"pmids\": [\"34644565\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular basis of sex bias (hormonal vs. genetic) not defined\", \"Whether senolytic therapy can reverse S64F-driven beta-cell dysfunction is unknown\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the identity of the E3 ubiquitin ligase(s) targeting MafA, the structural basis of phosphorylation-dependent dimerization and DNA binding, whether MafA-driven dedifferentiation is reversible in vivo, and the mechanism underlying sex-biased penetrance of MAFA S64F disease.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"E3 ubiquitin ligase for MafA not identified\", \"No crystal or cryo-EM structure of MafA or MafA–DNA complex\", \"Reversibility of dedifferentiation by MafA restoration not tested in vivo\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [0, 1, 11, 16, 17]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [0, 1, 2, 15, 24, 25, 30, 37]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [0, 8]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [0, 1, 2, 14, 15, 16, 17, 18, 24, 25]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [5, 6, 9, 10, 20, 21]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [6, 7, 8, 12, 13, 27]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [29, 35]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [3, 19, 28, 36]}\n    ],\n    \"complexes\": [\n      \"MLL3/MLL4 histone methyltransferase complex\"\n    ],\n    \"partners\": [\n      \"PDX1\",\n      \"NEUROD1\",\n      \"ATF2\",\n      \"PA28G\",\n      \"KINDLIN2\",\n      \"NCOA6\",\n      \"HMGA1\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"mechanistic_narrative\": \"Insufficient on-target evidence to synthesize a narrative — discovery timeline does not match the canonical MAFA protein.\",\n  \"teleology\": [],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [],\n    \"localization\": [],\n    \"pathway\": [],\n    \"complexes\": [],\n    \"partners\": [],\n    \"other_free_text\": []\n  }\n}\n```"}